<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="2016"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="1317" label="Small molecule therapeutic"/><FilterOption id="585" count="1064" label="Oral formulation"/><FilterOption id="648" count="827" label="Intravenous formulation"/><FilterOption id="761" count="787" label="Biological therapeutic"/><FilterOption id="595" count="774" label="Tablet formulation"/><FilterOption id="740" count="681" label="Infusion"/><FilterOption id="746" count="545" label="Solution"/><FilterOption id="751" count="526" label="Film coating"/><FilterOption id="586" count="507" label="Capsule formulation"/><FilterOption id="573" count="437" label="Immunoglobulin-G"/><FilterOption id="898" count="401" label="Formulation powder"/><FilterOption id="647" count="395" label="Subcutaneous formulation"/><FilterOption id="85" count="343" label="Protein recombinant"/><FilterOption id="750" count="332" label="Freeze drying"/><FilterOption id="169" count="282" label="Monoclonal antibody humanized"/><FilterOption id="1263" count="218" label="Immuno-oncology"/><FilterOption id="168" count="201" label="Monoclonal antibody human"/><FilterOption id="594" count="191" label="Oral suspension formulation"/><FilterOption id="1652" count="147" label="Prodrug"/><FilterOption id="1647" count="135" label="Natural product"/><FilterOption id="593" count="130" label="Oral liquid formulation"/><FilterOption id="80" count="124" label="Peptide"/><FilterOption id="175" count="122" label="Drug combination"/><FilterOption id="902" count="107" label="Orally disintegrating tablet"/><FilterOption id="805" count="104" label="Daily dosing"/><FilterOption id="589" count="100" label="Sustained release formulation"/><FilterOption id="651" count="83" label="Intramuscular formulation"/><FilterOption id="743" count="81" label="Granule"/><FilterOption id="766" count="80" label="Parenteral formulation unspecified"/><FilterOption id="745" count="71" label="Suspension"/><FilterOption id="894" count="70" label="Liquid formulation"/><FilterOption id="166" count="65" label="Chimeric monoclonal antibody"/><FilterOption id="180" count="55" label="Antibody fragment"/><FilterOption id="74" count="51" label="Glycoprotein"/><FilterOption id="66" count="50" label="Antibiotic"/><FilterOption id="128" count="48" label="Cell culture technique"/><FilterOption id="630" count="47" label="Stereochemistry"/><FilterOption id="84" count="46" label="Protein fusion"/><FilterOption id="667" count="45" label="Peptidomimetic"/><FilterOption id="90" count="45" label="Steroid"/><FilterOption id="680" count="41" label="Buccal formulation systemic"/><FilterOption id="596" count="41" label="Injectable formulation"/><FilterOption id="348" count="39" label="PEGylated formulation"/><FilterOption id="660" count="38" label="Oral sustained release formulation"/><FilterOption id="112" count="36" label="DNA technology"/><FilterOption id="603" count="36" label="Systemic formulation unspecified"/><FilterOption id="616" count="34" label="Inhalant formulation"/><FilterOption id="649" count="34" label="Intraperitoneal formulation"/><FilterOption id="171" count="34" label="Monoclonal antibody conjugated"/><FilterOption id="701" count="33" label="Nucleoside synthesis"/><FilterOption id="723" count="32" label="Drug coating"/><FilterOption id="1646" count="32" label="Injectable controlled release formulation"/><FilterOption id="641" count="31" label="Controlled release formulation"/><FilterOption id="742" count="31" label="Pellet"/><FilterOption id="852" count="30" label="Intravesical formulation"/><FilterOption id="127" count="26" label="Cell culture"/><FilterOption id="599" count="24" label="Nanoparticle formulation injectable"/><FilterOption id="102" count="23" label="Nucleotide and derivatives"/><FilterOption id="236" count="22" label="Macrolide"/><FilterOption id="159" count="21" label="Oligosaccharide"/><FilterOption id="618" count="20" label="Powder formulation inhalant"/><FilterOption id="207" count="20" label="Protein conjugated"/><FilterOption id="620" count="18" label="Ophthalmic formulation"/><FilterOption id="598" count="17" label="Liposome formulation injectable"/><FilterOption id="1164" count="16" label="Antibody drug conjugate"/><FilterOption id="611" count="16" label="Dermatological formulation"/><FilterOption id="167" count="15" label="Monoclonal antibody murine"/><FilterOption id="776" count="15" label="Oral gel formulation"/><FilterOption id="208" count="15" label="Protein conjugation"/><FilterOption id="662" count="15" label="Quick release formulation"/><FilterOption id="753" count="14" label="Microparticle formulation"/><FilterOption id="51" count="14" label="Monoclonal antibody"/><FilterOption id="617" count="13" label="Aerosol formulation inhalant"/><FilterOption id="590" count="13" label="Enteric coated formulation"/><FilterOption id="569" count="13" label="Oligonucleotide antisense"/><FilterOption id="1669" count="12" label="Emulsion formulation"/><FilterOption id="724" count="12" label="Radiolabeling"/><FilterOption id="558" count="12" label="Transdermal formulation"/><FilterOption id="62" count="12" label="Virus recombinant"/><FilterOption id="349" count="11" label="Lipid"/><FilterOption id="756" count="11" label="Pharmaceutical carrier"/><FilterOption id="537" count="10" label="Chimeric antibody"/><FilterOption id="851" count="10" label="Intradermal formulation"/><FilterOption id="347" count="10" label="Intratumoral formulation"/><FilterOption id="807" count="10" label="Monthly dosing"/><FilterOption id="731" count="9" label="Imaging"/><FilterOption id="103" count="9" label="Oligonucleotide"/><FilterOption id="661" count="9" label="Oral quick release formulation"/><FilterOption id="612" count="8" label="Emulsion dermatological"/><FilterOption id="652" count="8" label="Intra-articular formulation"/><FilterOption id="170" count="8" label="Multivalent monoclonal antibody"/><FilterOption id="559" count="8" label="Oral controlled release formulation"/><FilterOption id="342" count="8" label="Receptor fusion"/><FilterOption id="806" count="8" label="Weekly dosing"/><FilterOption id="582" count="7" label="Antibody polyclonal"/><FilterOption id="654" count="7" label="Intrathecal formulation"/><FilterOption id="764" count="7" label="Local formulation unspecified"/><FilterOption id="267" count="7" label="Multivalent antibody"/><FilterOption id="615" count="6" label="Aerosol formulation dermatological"/><FilterOption id="619" count="6" label="Nasal formulation local"/></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="3657" count="83" label="Metastatic breast cancer"/><FilterOption id="159" count="79" label="HIV-1 infection"/><FilterOption id="3665" count="68" label="Metastatic non small cell lung cancer"/><FilterOption id="2399" count="66" label="Adenocarcinoma"/><FilterOption id="1828" count="65" label="Multiple myeloma"/><FilterOption id="3257" count="64" label="Stage IV melanoma"/><FilterOption id="1069" count="50" label="Metastasis"/><FilterOption id="158" count="46" label="HIV infection"/><FilterOption id="3246" count="43" label="Hormone refractory prostate cancer"/><FilterOption id="837" count="39" label="Non-insulin dependent diabetes"/><FilterOption id="1731" count="38" label="Acute myelogenous leukemia"/><FilterOption id="307" count="38" label="Squamous cell carcinoma"/><FilterOption id="3256" count="38" label="Stage III melanoma"/><FilterOption id="49" count="36" label="Breast tumor"/><FilterOption id="3713" count="33" label="Advanced solid tumor"/><FilterOption id="3658" count="33" label="Metastatic colorectal cancer"/><FilterOption id="291" count="33" label="Rheumatoid arthritis"/><FilterOption id="1767" count="30" label="Hepatocellular carcinoma"/><FilterOption id="255" count="30" label="Parkinsons disease"/><FilterOption id="1771" count="30" label="Transitional cell carcinoma"/><FilterOption id="1734" count="29" label="Chronic lymphocytic leukemia"/><FilterOption id="213" count="28" label="Multiple sclerosis"/><FilterOption id="4250" count="27" label="Metastatic renal cell carcinoma"/><FilterOption id="14" count="26" label="Alzheimers disease"/><FilterOption id="84" count="26" label="Crohns disease"/><FilterOption id="337" count="26" label="Ulcerative colitis"/><FilterOption id="17" count="25" label="Anemia"/><FilterOption id="153" count="25" label="Hepatitis C virus infection"/><FilterOption id="31" count="24" label="Asthma"/><FilterOption id="3510" count="24" label="Pulmonary artery hypertension"/><FilterOption id="224" count="23" label="Myocardial infarction"/><FilterOption id="1542" count="22" label="Atrial fibrillation"/><FilterOption id="1185" count="22" label="Chronic obstructive pulmonary disease"/><FilterOption id="1272" count="21" label="Myelodysplastic syndrome"/><FilterOption id="1749" count="20" label="Diffuse large B-cell lymphoma"/><FilterOption id="1735" count="19" label="Chronic myelocytic leukemia"/><FilterOption id="80" count="19" label="Coronary artery disease"/><FilterOption id="836" count="19" label="Insulin dependent diabetes"/><FilterOption id="3667" count="19" label="Metastatic esophageal cancer"/><FilterOption id="319" count="19" label="Non-Hodgkin lymphoma"/><FilterOption id="3083" count="19" label="Peritoneal tumor"/><FilterOption id="2243" count="18" label="Fallopian tube cancer"/><FilterOption id="1745" count="18" label="Follicle center lymphoma"/><FilterOption id="70" count="18" label="Liver cirrhosis"/><FilterOption id="3673" count="18" label="Metastatic head and neck cancer"/><FilterOption id="3666" count="18" label="Metastatic stomach cancer"/><FilterOption id="55" count="17" label="Cardiac failure"/><FilterOption id="3466" count="17" label="Metastatic bladder cancer"/><FilterOption id="3669" count="17" label="Metastatic pancreas cancer"/><FilterOption id="799" count="17" label="Ovary tumor"/><FilterOption id="552" count="16" label="Bleeding"/><FilterOption id="1867" count="16" label="Pulmonary hypertension"/><FilterOption id="3866" count="15" label="Metastatic ovary cancer"/><FilterOption id="3664" count="15" label="Metastatic prostate cancer"/><FilterOption id="1262" count="15" label="Non-small-cell lung cancer"/><FilterOption id="1728" count="14" label="Acute lymphoblastic leukemia"/><FilterOption id="2454" count="14" label="Glioblastoma"/><FilterOption id="3676" count="14" label="Ischemic stroke"/><FilterOption id="299" count="14" label="Schizophrenia"/><FilterOption id="318" count="14" label="Systemic lupus erythematosus"/><FilterOption id="2989" count="13" label="Kidney transplant rejection"/><FilterOption id="20" count="13" label="Pain"/><FilterOption id="1705" count="12" label="Endometrioid carcinoma"/><FilterOption id="2984" count="12" label="Kidney transplantation"/><FilterOption id="2637" count="12" label="Non-alcoholic steatohepatitis"/><FilterOption id="325" count="12" label="Thromboembolism"/><FilterOption id="3258" count="11" label="Acute coronary syndrome"/><FilterOption id="989" count="11" label="Colorectal tumor"/><FilterOption id="3771" count="11" label="Idiopathic pulmonary fibrosis"/><FilterOption id="203" count="11" label="Lymphoma"/><FilterOption id="2436" count="11" label="Myelofibrosis"/><FilterOption id="360" count="11" label="Pneumonia"/><FilterOption id="1261" count="11" label="Small-cell lung cancer"/><FilterOption id="427" count="11" label="Uterine cervix tumor"/><FilterOption id="1815" count="10" label="Bacterial pneumonia"/><FilterOption id="760" count="10" label="Brain tumor"/><FilterOption id="57" count="10" label="Cardiovascular disease"/><FilterOption id="574" count="10" label="Deep vein thrombosis"/><FilterOption id="2983" count="10" label="Liver transplantation"/><FilterOption id="2319" count="10" label="Polycythemia vera"/><FilterOption id="152" count="9" label="Hepatitis B virus infection"/><FilterOption id="2317" count="9" label="Thrombocythemia"/><FilterOption id="1102" count="8" label="Atopic dermatitis"/><FilterOption id="316" count="8" label="B-cell lymphoma"/><FilterOption id="2432" count="8" label="Bronchiectasis"/><FilterOption id="1765" count="8" label="Cholangiocarcinoma"/><FilterOption id="174" count="8" label="Hypercholesterolemia"/><FilterOption id="3198" count="8" label="Larynx tumor"/><FilterOption id="1078" count="8" label="Lung embolism"/><FilterOption id="793" count="8" label="Mouth tumor"/><FilterOption id="245" count="8" label="Osteoarthritis"/><FilterOption id="1995" count="8" label="Primary biliary cholangitis"/><FilterOption id="1781" count="8" label="Psoriatic arthritis"/><FilterOption id="65" count="8" label="Stroke"/><FilterOption id="23" count="7" label="Angina"/><FilterOption id="3114" count="7" label="Bipolar I disorder"/><FilterOption id="2380" count="7" label="Bladder cancer"/><FilterOption id="161" count="7" label="Hodgkins disease"/><FilterOption id="205" count="7" label="Melanoma"/><FilterOption id="794" count="7" label="Pharynx tumor"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="9247" count="76" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8713" count="71" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8712" count="70" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9218" count="70" label="HIV infection - Assessment of Immune Response"/><FilterOption id="8719" count="69" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7879" count="67" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="8481" count="67" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8489" count="67" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9215" count="65" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="8998" count="64" label="Breast tumor - Assessment of adverse events"/><FilterOption id="9213" count="64" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="8078" count="61" label="Leukemia - Assessment of adverse events"/><FilterOption id="6919" count="58" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="7908" count="55" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8738" count="51" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="6940" count="50" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="8639" count="49" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="6924" count="49" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7538" count="48" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8721" count="46" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7547" count="46" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7027" count="46" label="Melanoma - Assessment of adverse events"/><FilterOption id="8077" count="44" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7354" count="43" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="7367" count="42" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7569" count="41" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8505" count="40" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7360" count="40" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8722" count="39" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8996" count="39" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="7891" count="39" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8663" count="39" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8720" count="38" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9153" count="38" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="9238" count="37" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8522" count="37" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="8640" count="37" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7680" count="37" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7909" count="36" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7563" count="35" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8430" count="34" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7611" count="34" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7489" count="34" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="7045" count="34" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9242" count="33" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7898" count="33" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="42921" count="33" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="6951" count="32" label="Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="7373" count="31" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="25660" count="31" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="22595" count="30" label="End stage renal disease - Assessment of adverse events"/><FilterOption id="9212" count="30" label="HIV infection - Assessment of Viral Load"/><FilterOption id="7679" count="30" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="7372" count="30" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7049" count="30" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7190" count="30" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9246" count="29" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="8514" count="29" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="29" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8744" count="28" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="9122" count="28" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8163" count="28" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9255" count="28" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="8109" count="28" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="2622" count="27" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="7393" count="27" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="10545" count="27" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15287" count="27" label="Solid tumor - Assessment of adverse events"/><FilterOption id="11717" count="26" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="37159" count="26" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8523" count="26" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8725" count="25" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="8759" count="25" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="9197" count="25" label="HIV infection - Assessment of virological response - Assessment of virological failure"/><FilterOption id="8140" count="25" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="6944" count="25" label="Melanoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7488" count="25" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="6863" count="24" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="7916" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="17356" count="23" label="Anemia - Assessment of adverse events"/><FilterOption id="8187" count="23" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="3736" count="23" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"/><FilterOption id="9272" count="23" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="9300" count="23" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7395" count="23" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="25708" count="23" label="Pulmonary artery hypertension - Assessment of Safety and Tolerability - Assessment of adverse effects"/><FilterOption id="11728" count="22" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8999" count="22" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8151" count="22" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="2492" count="22" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="7919" count="22" label="Leukemia - Assessment of Response Rates (RR) - Assessment of molecular response"/><FilterOption id="7564" count="22" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7025" count="22" label="Melanoma - Assessment of Safety and Tolerability"/><FilterOption id="26033" count="22" label="Pain - Assessment of adverse events"/><FilterOption id="2410" count="21" label="Alzheimers disease - Assessment of Safety and Tolerability"/><FilterOption id="17220" count="21" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="11722" count="21" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="5353" count="21" label="Kidney transplantation - Assessment of Safety and Tolerability"/><FilterOption id="8508" count="21" label="Lung tumor - Assessment of Overall Response"/><FilterOption id="10218" count="21" label="Parkinsons disease - Assessment of adverse events"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="12"><FilterOption id="L" count="1333" label="Launched"/><FilterOption id="C3" count="198" label="Phase 3 Clinical"/><FilterOption id="C2" count="167" label="Phase 2 Clinical"/><FilterOption id="DX" count="132" label="Discontinued"/><FilterOption id="PR" count="35" label="Pre-registration"/><FilterOption id="R" count="29" label="Registered"/><FilterOption id="NDR" count="27" label="No Development Reported"/><FilterOption id="C1" count="22" label="Phase 1 Clinical"/><FilterOption id="DR" count="12" label="Discovery"/><FilterOption id="W" count="10" label="Withdrawn"/><FilterOption id="CU" count="1" label="Clinical"/><FilterOption id="S" count="1" label="Suspended"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="19446" count="143" label="Roche Holding AG"/><FilterOption id="23137" count="124" label="Novartis AG"/><FilterOption id="1039423" count="113" label="Hospital Clinic of Barcelona"/><FilterOption id="18767" count="113" label="Pfizer Inc"/><FilterOption id="28355" count="88" label="GlaxoSmithKline plc"/><FilterOption id="14455" count="83" label="Bayer AG"/><FilterOption id="26178" count="77" label="F Hoffmann-La Roche AG"/><FilterOption id="15065" count="63" label="Bristol-Myers Squibb Co"/><FilterOption id="1038736" count="42" label="PETHEMA Foundation"/><FilterOption id="16450" count="38" label="Gilead Sciences Inc"/><FilterOption id="1003983" count="37" label="Bayer HealthCare AG"/><FilterOption id="1144568" count="37" label="Novartis Pharma Services AG"/><FilterOption id="1009547" count="37" label="Sanofi SA"/><FilterOption id="17810" count="36" label="Eli Lilly &amp; Co"/><FilterOption id="25599" count="36" label="Novartis Pharma AG"/><FilterOption id="14109" count="34" label="Amgen Inc"/><FilterOption id="14190" count="34" label="AstraZeneca plc"/><FilterOption id="15331" count="31" label="Celgene Corp"/><FilterOption id="1072507" count="30" label="AbbVie Inc"/><FilterOption id="14881" count="30" label="Boehringer Ingelheim International GmbH"/><FilterOption id="15133" count="25" label="Bristol-Myers Squibb International Corp"/><FilterOption id="30062" count="23" label="AstraZeneca AB"/><FilterOption id="29218" count="22" label="AbbVie Deutschland GmbH &amp; Co KG"/><FilterOption id="19453" count="22" label="Genentech Inc"/><FilterOption id="1050515" count="22" label="ViiV Healthcare Ltd"/><FilterOption id="15414" count="21" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1059823" count="19" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="23780" count="18" label="Actelion Ltd"/><FilterOption id="1067538" count="18" label="Janssen Research &amp; Development LLC"/><FilterOption id="1121088" count="18" label="Novartis Farmaceutica SA"/><FilterOption id="1119200" count="18" label="Sanofi-Aventis Research and Development"/><FilterOption id="1013295" count="16" label="Astellas Pharma Inc"/><FilterOption id="1042061" count="16" label="Spanish Breast Cancer Research Group"/><FilterOption id="13601" count="15" label="Abbott Laboratories"/><FilterOption id="1053612" count="15" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="1091809" count="15" label="Janssen-Cilag International NV (BE)"/><FilterOption id="27847" count="14" label="Boston Scientific Corp"/><FilterOption id="1145220" count="14" label="GlaxoSmithKline Research &amp; Development Ltd"/><FilterOption id="22546" count="13" label="Boehringer Ingelheim GmbH"/><FilterOption id="1110770" count="13" label="Novartis Farma SpA"/><FilterOption id="28611" count="12" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="15121" count="12" label="Bristol-Myers Squibb Belgium SA"/><FilterOption id="27053" count="12" label="Glaxo Group Research Ltd"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1095980" count="12" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."/><FilterOption id="1042371" count="12" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="1017513" count="11" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="1087775" count="11" label="Novartis Oncology"/><FilterOption id="18614" count="10" label="Novo Nordisk A/S"/><FilterOption id="1143375" count="9" label="AbbVie Pte Ltd"/><FilterOption id="1005244" count="9" label="Biogen Inc"/><FilterOption id="22554" count="9" label="Boehringer Ingelheim BV"/><FilterOption id="17839" count="9" label="Eli Lilly SA"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="22586" count="8" label="Boehringer Ingelheim Corp"/><FilterOption id="1103352" count="8" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="22563" count="8" label="Boehringer Ingelheim Ltd"/><FilterOption id="1020322" count="8" label="Daiichi Sankyo Inc"/><FilterOption id="1051470" count="8" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="1052299" count="8" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="1003065" count="8" label="Hospital Vall D'Hebron"/><FilterOption id="18008" count="8" label="MedImmune LLC"/><FilterOption id="1058600" count="8" label="Novartis India"/><FilterOption id="19063" count="8" label="Pharmacyclics Inc"/><FilterOption id="21991" count="8" label="Takeda Oncology"/><FilterOption id="13979" count="7" label="Alexion Pharmaceuticals Inc"/><FilterOption id="25902" count="7" label="Array BioPharma Inc"/><FilterOption id="20972" count="7" label="Astellas Pharma Europe Ltd"/><FilterOption id="1039086" count="7" label="Germans Trias i Pujol Hospital"/><FilterOption id="27108" count="7" label="Glaxo SA"/><FilterOption id="24166" count="7" label="GlaxoSmithKline Biologicals"/><FilterOption id="19461" count="7" label="Hoffmann-La Roche Inc"/><FilterOption id="17259" count="7" label="Ipsen"/><FilterOption id="1048099" count="7" label="Queen Mary Hospital"/><FilterOption id="1122528" count="7" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="22598" count="7" label="Unilfarma Lda"/><FilterOption id="22549" count="6" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="17002" count="6" label="Human Genome Sciences Inc"/><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"/><FilterOption id="1097361" count="6" label="Medtronic plc"/><FilterOption id="1090120" count="6" label="NOVARTIS (SINGAPORE) PTE LTD"/><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"/><FilterOption id="24968" count="5" label="Arena Pharmaceuticals Inc"/><FilterOption id="1110884" count="5" label="Biogen Idec Research Ltd"/><FilterOption id="22556" count="5" label="Boehringer Ingelheim France SARL"/><FilterOption id="1007640" count="5" label="CSL Behring LLC"/><FilterOption id="19620" count="5" label="Eisai Inc"/><FilterOption id="14913" count="5" label="Eisai Ltd"/><FilterOption id="1042252" count="5" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="17216" count="5" label="Incyte Corp"/><FilterOption id="1017771" count="5" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="1090417" count="5" label="Roche Singapore Pte Ltd"/><FilterOption id="24652" count="5" label="Shire plc"/><FilterOption id="1073757" count="5" label="Spanish Society of Cardiology"/><FilterOption id="25439" count="5" label="United Therapeutics Corp"/><FilterOption id="14112" count="5" label="Wyeth"/><FilterOption id="14296" count="4" label="ARIAD Pharmaceuticals Inc"/><FilterOption id="1037956" count="4" label="Astellas Pharma Global Development Inc"/><FilterOption id="22545" count="4" label="Boehringer Ingelheim AB"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="1065" label="Completed"/><FilterOption id="2" count="407" label="Recruiting"/><FilterOption id="3" count="317" label="No longer recruiting"/><FilterOption id="6" count="191" label="Terminated"/><FilterOption id="1" count="29" label="Not yet recruiting"/><FilterOption id="5" count="6" label="Suspended"/><FilterOption id="12" count="1" label="Status not specified"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="1313" label="Yes"/><FilterOption id="NO" count="703" label="No"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="3657" count="22" label="Metastatic breast cancer"/><FilterOption id="2399" count="21" label="Adenocarcinoma"/><FilterOption id="1069" count="16" label="Metastasis"/><FilterOption id="3665" count="16" label="Metastatic non small cell lung cancer"/><FilterOption id="3713" count="15" label="Advanced solid tumor"/><FilterOption id="3658" count="14" label="Metastatic colorectal cancer"/><FilterOption id="307" count="14" label="Squamous cell carcinoma"/><FilterOption id="1767" count="12" label="Hepatocellular carcinoma"/><FilterOption id="3669" count="12" label="Metastatic pancreas cancer"/><FilterOption id="3257" count="11" label="Stage IV melanoma"/><FilterOption id="159" count="10" label="HIV-1 infection"/><FilterOption id="3246" count="10" label="Hormone refractory prostate cancer"/><FilterOption id="3667" count="10" label="Metastatic esophageal cancer"/><FilterOption id="3673" count="10" label="Metastatic head and neck cancer"/><FilterOption id="1771" count="10" label="Transitional cell carcinoma"/><FilterOption id="1731" count="9" label="Acute myelogenous leukemia"/><FilterOption id="3256" count="9" label="Stage III melanoma"/><FilterOption id="3466" count="8" label="Metastatic bladder cancer"/><FilterOption id="1828" count="8" label="Multiple myeloma"/><FilterOption id="1272" count="8" label="Myelodysplastic syndrome"/><FilterOption id="224" count="8" label="Myocardial infarction"/><FilterOption id="1815" count="7" label="Bacterial pneumonia"/><FilterOption id="84" count="7" label="Crohns disease"/><FilterOption id="3676" count="7" label="Ischemic stroke"/><FilterOption id="3866" count="7" label="Metastatic ovary cancer"/><FilterOption id="3664" count="7" label="Metastatic prostate cancer"/><FilterOption id="3666" count="7" label="Metastatic stomach cancer"/><FilterOption id="158" count="6" label="HIV infection"/><FilterOption id="319" count="6" label="Non-Hodgkin lymphoma"/><FilterOption id="837" count="6" label="Non-insulin dependent diabetes"/><FilterOption id="1261" count="6" label="Small-cell lung cancer"/><FilterOption id="427" count="6" label="Uterine cervix tumor"/><FilterOption id="14" count="5" label="Alzheimers disease"/><FilterOption id="760" count="5" label="Brain tumor"/><FilterOption id="1705" count="5" label="Endometrioid carcinoma"/><FilterOption id="2454" count="5" label="Glioblastoma"/><FilterOption id="3771" count="5" label="Idiopathic pulmonary fibrosis"/><FilterOption id="70" count="5" label="Liver cirrhosis"/><FilterOption id="1240" count="5" label="Mesothelioma"/><FilterOption id="4250" count="5" label="Metastatic renal cell carcinoma"/><FilterOption id="793" count="5" label="Mouth tumor"/><FilterOption id="799" count="5" label="Ovary tumor"/><FilterOption id="3510" count="5" label="Pulmonary artery hypertension"/><FilterOption id="337" count="5" label="Ulcerative colitis"/><FilterOption id="1728" count="4" label="Acute lymphoblastic leukemia"/><FilterOption id="2193" count="4" label="Anal tumor"/><FilterOption id="2432" count="4" label="Bronchiectasis"/><FilterOption id="989" count="4" label="Colorectal tumor"/><FilterOption id="1745" count="4" label="Follicle center lymphoma"/><FilterOption id="3198" count="4" label="Larynx tumor"/><FilterOption id="3235" count="4" label="Merkel cell carcinoma"/><FilterOption id="794" count="4" label="Pharynx tumor"/><FilterOption id="1867" count="4" label="Pulmonary hypertension"/><FilterOption id="286" count="4" label="Renal disease"/><FilterOption id="3258" count="3" label="Acute coronary syndrome"/><FilterOption id="3395" count="3" label="Acute liver failure"/><FilterOption id="49" count="3" label="Breast tumor"/><FilterOption id="57" count="3" label="Cardiovascular disease"/><FilterOption id="1765" count="3" label="Cholangiocarcinoma"/><FilterOption id="3919" count="3" label="Chronic liver failure"/><FilterOption id="1734" count="3" label="Chronic lymphocytic leukemia"/><FilterOption id="1735" count="3" label="Chronic myelocytic leukemia"/><FilterOption id="3689" count="3" label="Compensated liver cirrhosis"/><FilterOption id="574" count="3" label="Deep vein thrombosis"/><FilterOption id="100" count="3" label="Diabetic nephropathy"/><FilterOption id="1749" count="3" label="Diffuse large B-cell lymphoma"/><FilterOption id="113" count="3" label="Endometriosis"/><FilterOption id="2212" count="3" label="Hepatorenal syndrome"/><FilterOption id="170" count="3" label="Huntingtons chorea"/><FilterOption id="2989" count="3" label="Kidney transplant rejection"/><FilterOption id="584" count="3" label="Lipid metabolism disorder"/><FilterOption id="2318" count="3" label="Liver fibrosis"/><FilterOption id="1078" count="3" label="Lung embolism"/><FilterOption id="2404" count="3" label="Lupus nephritis"/><FilterOption id="3467" count="3" label="Metastatic renal cancer"/><FilterOption id="1262" count="3" label="Non-small-cell lung cancer"/><FilterOption id="360" count="3" label="Pneumonia"/><FilterOption id="3239" count="3" label="Portal hypertension"/><FilterOption id="1727" count="2" label="Acute leukemia"/><FilterOption id="2567" count="2" label="Anaplastic astrocytoma"/><FilterOption id="17" count="2" label="Anemia"/><FilterOption id="1729" count="2" label="B-cell acute lymphoblastic leukemia"/><FilterOption id="316" count="2" label="B-cell lymphoma"/><FilterOption id="1516" count="2" label="Biliary cancer"/><FilterOption id="2380" count="2" label="Bladder cancer"/><FilterOption id="651" count="2" label="Cancer"/><FilterOption id="1308" count="2" label="Candida infection"/><FilterOption id="2217" count="2" label="Cholestasis"/><FilterOption id="97" count="2" label="Diabetes mellitus"/><FilterOption id="1011" count="2" label="Esophagus tumor"/><FilterOption id="2243" count="2" label="Fallopian tube cancer"/><FilterOption id="1127" count="2" label="Fibrosis"/><FilterOption id="2054" count="2" label="Hematological neoplasm"/><FilterOption id="152" count="2" label="Hepatitis B virus infection"/><FilterOption id="153" count="2" label="Hepatitis C virus infection"/><FilterOption id="161" count="2" label="Hodgkins disease"/><FilterOption id="836" count="2" label="Insulin dependent diabetes"/><FilterOption id="2984" count="2" label="Kidney transplantation"/><FilterOption id="2988" count="2" label="Liver transplant rejection"/><FilterOption id="203" count="2" label="Lymphoma"/></Filter><Filter label="Registry Id" name="trialRegistries" total="25"><FilterOption id="1000" count="1999" label="CT.gov"/><FilterOption id="1001" count="1466" label="EudraCT"/><FilterOption id="1030" count="313" label="RSRM CTR"/><FilterOption id="1006" count="228" label="JapicCTI"/><FilterOption id="1023" count="157" label="UKCRN"/><FilterOption id="1019" count="137" label="DRKS"/><FilterOption id="1035" count="87" label="Singapore HSA CTR"/><FilterOption id="1012" count="83" label="CTRI"/><FilterOption id="1004" count="80" label="WHO ICTRP"/><FilterOption id="1021" count="71" label="NMRR"/><FilterOption id="1039" count="49" label="CDE"/><FilterOption id="1009" count="48" label="HKClinicalTrials.com"/><FilterOption id="1033" count="39" label="Mexico CTR"/><FilterOption id="1038" count="28" label="PHRR"/><FilterOption id="1002" count="25" label="ISRCTN"/><FilterOption id="1011" count="22" label="ANZCTR"/><FilterOption id="1008" count="7" label="Hong Kong CCTCTR"/><FilterOption id="1020" count="7" label="ReBec"/><FilterOption id="1010" count="6" label="CRiS"/><FilterOption id="1015" count="4" label="NTR"/><FilterOption id="1040" count="4" label="REec"/><FilterOption id="1003" count="3" label="UMIN"/><FilterOption id="1016" count="2" label="PACTR"/><FilterOption id="1018" count="2" label="SLCTR"/><FilterOption id="1007" count="1" label="ChiCTR"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="1" count="52" label="Lack of Efficacy"/><FilterOption id="5" count="39" label="Patient Enrollment Issues"/><FilterOption id="2" count="36" label="Not Reported"/><FilterOption id="4" count="31" label="Other"/><FilterOption id="8" count="27" label="Sponsor/Business Decision"/><FilterOption id="7" count="16" label="Safety Issues"/><FilterOption id="3" count="6" label="Operational Issues"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="3803" count="31" label="paclitaxel"/><FilterOption id="2953" count="30" label="docetaxel"/><FilterOption id="44383" count="28" label="carboplatin"/><FilterOption id="3199" count="26" label="gemcitabine"/><FilterOption id="12205" count="16" label="capecitabine"/><FilterOption id="49219" count="16" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="13928" count="15" label="enoxaparin sodium"/><FilterOption id="7310" count="14" label="ritonavir"/><FilterOption id="6736" count="14" label="rituximab"/><FilterOption id="6386" count="13" label="trastuzumab"/><FilterOption id="4510" count="11" label="tacrolimus"/><FilterOption id="37370" count="10" label="azacitidine"/><FilterOption id="3792" count="10" label="oxaliplatin"/><FilterOption id="15954" count="9" label="bortezomib"/><FilterOption id="7413" count="9" label="darbepoetin alfa"/><FilterOption id="3669" count="9" label="mycophenolate mofetil"/><FilterOption id="15254" count="8" label="atazanavir"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="3313" count="8" label="fulvestrant"/><FilterOption id="14681" count="8" label="lopinavir + ritonavir"/><FilterOption id="6050" count="8" label="metformin hydrochloride"/><FilterOption id="3536" count="8" label="pemetrexed disodium"/><FilterOption id="4529" count="8" label="temozolomide"/><FilterOption id="44375" count="8" label="warfarin"/><FilterOption id="10309" count="7" label="abiraterone"/><FilterOption id="32981" count="7" label="darunavir"/><FilterOption id="10172" count="7" label="efavirenz"/><FilterOption id="3072" count="7" label="etoposide phosphate"/><FilterOption id="11460" count="7" label="imatinib"/><FilterOption id="2836" count="6" label="clopidogrel"/><FilterOption id="7934" count="6" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="3081" count="6" label="exemestane"/><FilterOption id="48181" count="6" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="27572" count="6" label="lenalidomide"/><FilterOption id="2784" count="6" label="letrozole"/><FilterOption id="54804" count="6" label="nivolumab"/><FilterOption id="12973" count="6" label="sunitinib"/><FilterOption id="14493" count="6" label="tenofovir disoproxil fumarate"/><FilterOption id="44401" count="6" label="vancomycin"/><FilterOption id="47000" count="5" label="bendamustine"/><FilterOption id="10388" count="5" label="cetuximab"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="10252" count="5" label="insulin glargine"/><FilterOption id="36630" count="5" label="ipilimumab"/><FilterOption id="33591" count="5" label="lapatinib"/><FilterOption id="54488" count="5" label="raltegravir"/><FilterOption id="5369" count="5" label="ribavirin"/><FilterOption id="29831" count="5" label="sorafenib"/><FilterOption id="4577" count="5" label="topotecan"/><FilterOption id="6408" count="5" label="vinorelbine"/><FilterOption id="14163" count="4" label="adalimumab"/><FilterOption id="3321" count="4" label="anastrozole"/><FilterOption id="54601" count="4" label="carfilzomib"/><FilterOption id="5999" count="4" label="ciclosporin, Novartis"/><FilterOption id="13239" count="4" label="decitabine"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="13340" count="4" label="everolimus"/><FilterOption id="8832" count="4" label="glimepiride"/><FilterOption id="3353" count="4" label="insulin lispro"/><FilterOption id="5267" count="4" label="leuprorelin acetate"/><FilterOption id="11519" count="4" label="mitoxantrone"/><FilterOption id="23625" count="4" label="peginterferon alfa-2a"/><FilterOption id="70667" count="4" label="pembrolizumab"/><FilterOption id="44313" count="4" label="simvastatin"/><FilterOption id="12150" count="4" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="72699" count="3" label="atezolizumab"/><FilterOption id="12544" count="3" label="caspofungin"/><FilterOption id="44384" count="3" label="ceftriaxone"/><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="59062" count="3" label="dolutegravir"/><FilterOption id="25880" count="3" label="enteric-coated mycophenolate sodium, Novartis"/><FilterOption id="11961" count="3" label="erlotinib"/><FilterOption id="6156" count="3" label="fludarabine"/><FilterOption id="2871" count="3" label="irinotecan"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="42299" count="3" label="ofatumumab"/><FilterOption id="29016" count="3" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="8713" count="3" label="sildenafil citrate"/><FilterOption id="54469" count="3" label="vemurafenib"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="11141" count="2" label="basiliximab"/><FilterOption id="44388" count="2" label="carbidopa + levodopa"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53133" count="2" label="dabrafenib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="2992" count="2" label="donepezil hydrochloride"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="67892" count="2" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"/><FilterOption id="28773" count="2" label="eribulin mesylate"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="3130" count="2" label="filgrastim"/><FilterOption id="3350" count="2" label="Fluarix"/><FilterOption id="44292" count="2" label="fluconazole"/><FilterOption id="3159" count="2" label="fluticasone propionate"/><FilterOption id="24471" count="2" label="fosamprenavir"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6859" count="97" label="HIV infection - Pregnant or Breast Feeding Subjects"/><FilterOption id="6554" count="86" label="Leukemia - Subjects with Co-morbid Conditions"/><FilterOption id="6258" count="72" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="6845" count="68" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6247" count="63" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"/><FilterOption id="6294" count="60" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5132" count="57" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="4702" count="56" label="Lymphoma - Subjects with Co-morbid Conditions"/><FilterOption id="6393" count="55" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="6892" count="54" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="20282" count="53" label="Lung tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6820" count="52" label="HIV infection - Subjects with Opportunistic/Other Infections"/><FilterOption id="6272" count="51" label="Breast tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6941" count="51" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="6534" count="51" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5125" count="51" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"/><FilterOption id="6065" count="51" label="Multiple myeloma - Subjects with Co-morbid Conditions"/><FilterOption id="5193" count="50" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6331" count="49" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6377" count="47" label="Breast tumor - Subjects with history of/planned radiotherapy"/><FilterOption id="5365" count="46" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="5291" count="46" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="5405" count="46" label="Melanoma - Subjects with Evidence of Metastasis - Subjects with central nervous system metastasis"/><FilterOption id="6660" count="43" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="5470" count="43" label="Melanoma - Subjects co-morbid with inflammatory disorders"/><FilterOption id="5270" count="42" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4692" count="40" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6328" count="39" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"/><FilterOption id="6951" count="39" label="HIV infection - Subjects with AIDS/AIDS Defining Events"/><FilterOption id="6260" count="38" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="5345" count="38" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="5414" count="38" label="Melanoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5282" count="37" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="6302" count="36" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="6843" count="36" label="HIV infection - Subjects with Co-morbid Conditions"/><FilterOption id="6963" count="36" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication - Subjects with history/scheduled to receive immunomodulators for other indication"/><FilterOption id="5547" count="36" label="Melanoma - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="5139" count="35" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="4967" count="35" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="10704" count="35" label="Solid tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6082" count="34" label="Multiple myeloma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4847" count="34" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"/><FilterOption id="6253" count="33" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"/><FilterOption id="20290" count="33" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="9412" count="33" label="Hepatobiliary system tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6863" count="33" label="HIV infection - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"/><FilterOption id="6850" count="33" label="HIV infection - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6756" count="33" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"/><FilterOption id="4769" count="33" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="5430" count="33" label="Melanoma - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="4909" count="33" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6259" count="32" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="6252" count="32" label="Breast tumor - Subjects with Co-morbid Conditions"/><FilterOption id="17519" count="32" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5128" count="32" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="17531" count="31" label="End stage renal disease - Subjects co-morbid with infections"/><FilterOption id="6862" count="31" label="HIV infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="5349" count="31" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"/><FilterOption id="5521" count="30" label="Melanoma - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="6474" count="29" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="6618" count="29" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4968" count="29" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects on prior/concurrent radiotherapy"/><FilterOption id="17557" count="28" label="Breast tumor - Subjects with Abnormal Laboratory Findings"/><FilterOption id="17533" count="28" label="End stage renal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="17541" count="28" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"/><FilterOption id="5149" count="28" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6783" count="28" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for immunotherapy"/><FilterOption id="24372" count="28" label="Other gastrointestinal disease - Subjects with Protocol Specified Reproductive Status - Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception"/><FilterOption id="4864" count="28" label="Prostate tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="9003" count="27" label="Bladder cancer - Subjects with Co-morbid Conditions"/><FilterOption id="6860" count="27" label="HIV infection - Subjects with Abnormal Laboratory Findings"/><FilterOption id="5426" count="27" label="Melanoma - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="5529" count="27" label="Melanoma - Subjects with History of/Scheduled for Other Treatment Modalities of Melanoma - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="6940" count="26" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication - Subjects on treatment for malignancy"/><FilterOption id="6530" count="26" label="Leukemia - Leukemia Subjects with Advanced Disease - Subjects with central nervous system involvement of leukemia"/><FilterOption id="5163" count="26" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6767" count="26" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"/><FilterOption id="4810" count="26" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="20289" count="25" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"/><FilterOption id="7555" count="25" label="HIV infection - Subjects with Progressive/Treatment Refractory Disease - Subjects with resistant mutations"/><FilterOption id="6504" count="25" label="Leukemia - Subjects with Acute Myeloid Leukemia - Subjects with promyelocytic leukemia (M3)"/><FilterOption id="5285" count="25" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="5269" count="25" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="6361" count="24" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"/><FilterOption id="20292" count="24" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="4718" count="24" label="Lymphoma - Subjects co-morbid with infections - Subjects co-morbid with HIV infection"/><FilterOption id="4730" count="24" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"/><FilterOption id="10761" count="24" label="Solid tumor - Subjects with Evidence of Metastasis - Subjects with brain/CNS metastasis"/><FilterOption id="5841" count="23" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6133" count="23" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="3058" count="22" label="Chronic obstructive pulmonary disease - Subjects co-morbid with Respiratory Diseases/Disorders"/><FilterOption id="4739" count="22" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"/><FilterOption id="25158" count="22" label="Other gastrointestinal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="9810" count="22" label="Ovary tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6645" count="21" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="5522" count="21" label="Melanoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="25164" count="21" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="20114" count="21" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"/><FilterOption id="17539" count="20" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified transplantation related criteria"/><FilterOption id="6874" count="20" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Drugs"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="17" label="201906"/><FilterOption count="16" label="201509"/><FilterOption count="15" label="201605"/><FilterOption count="15" label="201708"/><FilterOption count="14" label="201705"/><FilterOption count="14" label="201810"/><FilterOption count="14" label="201904"/><FilterOption count="13" label="201310"/><FilterOption count="13" label="201402"/><FilterOption count="13" label="201608"/><FilterOption count="13" label="201905"/><FilterOption count="12" label="201505"/><FilterOption count="12" label="201512"/><FilterOption count="12" label="201603"/><FilterOption count="12" label="201607"/><FilterOption count="12" label="201612"/><FilterOption count="12" label="201711"/><FilterOption count="12" label="201902"/><FilterOption count="11" label="200910"/><FilterOption count="11" label="201110"/><FilterOption count="11" label="201210"/><FilterOption count="11" label="201411"/><FilterOption count="11" label="201506"/><FilterOption count="11" label="201601"/><FilterOption count="11" label="201712"/><FilterOption count="11" label="201802"/><FilterOption count="11" label="201803"/><FilterOption count="11" label="201808"/><FilterOption count="10" label="201209"/><FilterOption count="10" label="201301"/><FilterOption count="10" label="201312"/><FilterOption count="10" label="201710"/><FilterOption count="10" label="201804"/><FilterOption count="10" label="201806"/><FilterOption count="10" label="201807"/><FilterOption count="10" label="201812"/><FilterOption count="9" label="200909"/><FilterOption count="9" label="201003"/><FilterOption count="9" label="201103"/><FilterOption count="9" label="201112"/><FilterOption count="9" label="201203"/><FilterOption count="9" label="201306"/><FilterOption count="9" label="201307"/><FilterOption count="9" label="201311"/><FilterOption count="9" label="201404"/><FilterOption count="9" label="201503"/><FilterOption count="9" label="201510"/><FilterOption count="9" label="201706"/><FilterOption count="9" label="201801"/><FilterOption count="9" label="201805"/><FilterOption count="9" label="201901"/><FilterOption count="8" label="200906"/><FilterOption count="8" label="201401"/><FilterOption count="8" label="201408"/><FilterOption count="8" label="201502"/><FilterOption count="8" label="201604"/><FilterOption count="8" label="201609"/><FilterOption count="8" label="201610"/><FilterOption count="8" label="201701"/><FilterOption count="8" label="201702"/><FilterOption count="8" label="201703"/><FilterOption count="8" label="201811"/><FilterOption count="8" label="201903"/><FilterOption count="7" label="200905"/><FilterOption count="7" label="200908"/><FilterOption count="7" label="201001"/><FilterOption count="7" label="201202"/><FilterOption count="7" label="201207"/><FilterOption count="7" label="201302"/><FilterOption count="7" label="201305"/><FilterOption count="7" label="201308"/><FilterOption count="7" label="201405"/><FilterOption count="7" label="201409"/><FilterOption count="7" label="201412"/><FilterOption count="7" label="201504"/><FilterOption count="7" label="201511"/><FilterOption count="7" label="201709"/><FilterOption count="6" label="200810"/><FilterOption count="6" label="200811"/><FilterOption count="6" label="201002"/><FilterOption count="6" label="201007"/><FilterOption count="6" label="201010"/><FilterOption count="6" label="201101"/><FilterOption count="6" label="201105"/><FilterOption count="6" label="201106"/><FilterOption count="6" label="201108"/><FilterOption count="6" label="201204"/><FilterOption count="6" label="201309"/><FilterOption count="6" label="201410"/><FilterOption count="6" label="201507"/><FilterOption count="6" label="201508"/><FilterOption count="6" label="201606"/><FilterOption count="6" label="201704"/><FilterOption count="6" label="201809"/><FilterOption count="5" label="200609"/><FilterOption count="5" label="200611"/><FilterOption count="5" label="200612"/><FilterOption count="5" label="200706"/><FilterOption count="5" label="201004"/><FilterOption count="5" label="201009"/></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="1687" label="Company"/><FilterOption id="ACA" count="496" label="Academic"/><FilterOption id="GOV" count="22" label="Government"/><FilterOption id="OTH" count="14" label="Others"/><FilterOption id="NGO" count="4" label="Non-Government"/></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="2013" label="Northern, Southern &amp; Western Europe"/><FilterOption id="USCA" count="1229" label="US &amp; Canada"/><FilterOption id="EEUR" count="1086" label="Eastern Europe"/><FilterOption id="AUNZ" count="731" label="Australia &amp; New Zealand"/><FilterOption id="EAPO" count="669" label="East Asia &amp; Pacific Ocean"/><FilterOption id="MENA" count="613" label="Middle East &amp; North Africa"/><FilterOption id="SOAM" count="569" label="South America"/><FilterOption id="CAAC" count="428" label="Central America &amp; Caribbean"/><FilterOption id="CSAF" count="284" label="Central &amp; Southern Africa"/><FilterOption id="SOCA" count="166" label="Southern &amp; Central Asia"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="7126" count="110" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"/><FilterOption id="3954" count="77" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"/><FilterOption id="3634" count="70" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"/><FilterOption id="3617" count="63" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3680" count="54" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="3667" count="52" label="Melanoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="10295" count="50" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"/><FilterOption id="3937" count="49" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3965" count="44" label="Breast tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3564" count="44" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"/><FilterOption id="3977" count="43" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3952" count="40" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"/><FilterOption id="3698" count="38" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"/><FilterOption id="3926" count="38" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"/><FilterOption id="3931" count="36" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="3824" count="36" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"/><FilterOption id="3530" count="36" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="3936" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="3623" count="35" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"/><FilterOption id="3923" count="35" label="Multiple myeloma - Subjects with Treatment Resistant Disease"/><FilterOption id="3966" count="33" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"/><FilterOption id="7108" count="33" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="3525" count="33" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="3583" count="33" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="7107" count="32" label="HIV infection - Treatment Naive Subjects"/><FilterOption id="3681" count="32" label="Melanoma - Subjects with Evidence of Metastasis"/><FilterOption id="3999" count="30" label="Leukemia - Subjects with Treatment Resistant Disease"/><FilterOption id="4003" count="29" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"/><FilterOption id="7961" count="29" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"/><FilterOption id="3980" count="28" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"/><FilterOption id="3975" count="27" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="3565" count="27" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="461" count="26" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"/><FilterOption id="3647" count="26" label="Lung tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3500" count="26" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3586" count="26" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="7415" count="26" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"/><FilterOption id="12018" count="25" label="Prostate tumor - Subjects with adenocarcinoma of prostate"/><FilterOption id="3472" count="24" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3676" count="24" label="Melanoma - Subjects with Stage III Melanoma"/><FilterOption id="7810" count="23" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"/><FilterOption id="3932" count="23" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="12845" count="22" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"/><FilterOption id="3814" count="22" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="7700" count="22" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"/><FilterOption id="12053" count="22" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="3473" count="22" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3956" count="21" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"/><FilterOption id="12889" count="21" label="Leukemia - Subjects with gene variants - BCR_ABL1_HUMAN_Fusion"/><FilterOption id="3489" count="21" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3679" count="21" label="Melanoma - Subjects with Stage III Melanoma - Subjects with stage IIIC melanoma"/><FilterOption id="3870" count="21" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="7402" count="21" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"/><FilterOption id="7967" count="21" label="Solid tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="7809" count="20" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="3938" count="20" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="3813" count="20" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="3774" count="20" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"/><FilterOption id="7109" count="20" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors"/><FilterOption id="3502" count="20" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="11242" count="20" label="Pulmonary artery hypertension - Subjects with Idiopathic PAH (IPAH)"/><FilterOption id="7414" count="20" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"/><FilterOption id="3950" count="19" label="Breast tumor - Subjects with Early Stage Breast Cancer"/><FilterOption id="3976" count="19" label="Leukemia - Subjects with Chronic Leukemia Unspecified Type"/><FilterOption id="103" count="19" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"/><FilterOption id="7879" count="19" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"/><FilterOption id="7806" count="18" label="Bladder cancer - Subjects with Locally Advanced Bladder Cancer"/><FilterOption id="600" count="18" label="Kidney transplantation - Renal Transplant Recipients"/><FilterOption id="128" count="18" label="Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)"/><FilterOption id="145" count="18" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"/><FilterOption id="8010" count="18" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"/><FilterOption id="161" count="17" label="Alzheimers disease - Subjects with Mild Alzheimer's Disease"/><FilterOption id="3944" count="17" label="Breast tumor - Subjects with Stage II Breast Cancer"/><FilterOption id="3945" count="17" label="Breast tumor - Subjects with Stage III Breast Cancer"/><FilterOption id="7877" count="17" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"/><FilterOption id="14611" count="17" label="Melanoma - Subjects with gene variants - BRAF_HUMAN_Mutation(codon600)"/><FilterOption id="7054" count="17" label="Melanoma - Subjects with specific disease - Subjects with Cutaneous Melanoma"/><FilterOption id="11954" count="16" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"/><FilterOption id="201" count="16" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"/><FilterOption id="3979" count="16" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3650" count="16" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"/><FilterOption id="3710" count="16" label="Melanoma - Subjects with Treatment Resistant Disease"/><FilterOption id="19047" count="16" label="Melanoma - Treatment Naive Subjects"/><FilterOption id="8073" count="16" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"/><FilterOption id="502" count="16" label="Rheumatoid arthritis - Active Rheumatoid Arthritis"/><FilterOption id="11631" count="16" label="Stroke - Subjects with Ischemic Stroke"/><FilterOption id="8776" count="16" label="Ulcerative colitis - Subjects with Moderate to Severe Ulcerative Colitis"/><FilterOption id="561" count="15" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD"/><FilterOption id="368" count="15" label="Coronary artery disease - Subjects with Myocardial Ischemia"/><FilterOption id="3404" count="15" label="Crohns disease - Subjects with Active Crohns Disease"/><FilterOption id="3778" count="15" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"/><FilterOption id="3978" count="15" label="Leukemia - Subjects with Chronic Myeloid Leukemia (CML)"/><FilterOption id="562" count="14" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD"/><FilterOption id="3754" count="14" label="Crohns disease - Subjects with Moderate to Severe Crohns Disease"/><FilterOption id="634" count="14" label="Liver transplantation - Liver Transplant Recipients"/><FilterOption id="7894" count="14" label="Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer"/><FilterOption id="3571" count="14" label="Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy"/><FilterOption id="8784" count="14" label="Ulcerative colitis - Subjects with Active Ulcerative Colitis"/><FilterOption id="11963" count="13" label="Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs"/><FilterOption id="77" count="13" label="Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="41" label="201912"/><FilterOption count="25" label="201906"/><FilterOption count="23" label="202012"/><FilterOption count="21" label="201810"/><FilterOption count="21" label="201909"/><FilterOption count="20" label="202001"/><FilterOption count="19" label="201512"/><FilterOption count="19" label="201707"/><FilterOption count="19" label="201911"/><FilterOption count="19" label="202004"/><FilterOption count="19" label="202007"/><FilterOption count="18" label="201905"/><FilterOption count="18" label="202006"/><FilterOption count="17" label="201507"/><FilterOption count="17" label="201705"/><FilterOption count="17" label="201812"/><FilterOption count="17" label="201908"/><FilterOption count="17" label="202003"/><FilterOption count="16" label="201612"/><FilterOption count="16" label="201803"/><FilterOption count="16" label="201907"/><FilterOption count="16" label="202011"/><FilterOption count="16" label="202103"/><FilterOption count="15" label="201409"/><FilterOption count="15" label="201611"/><FilterOption count="15" label="201710"/><FilterOption count="15" label="201910"/><FilterOption count="14" label="201310"/><FilterOption count="14" label="202009"/><FilterOption count="14" label="202106"/><FilterOption count="13" label="201206"/><FilterOption count="13" label="201604"/><FilterOption count="13" label="201605"/><FilterOption count="13" label="201606"/><FilterOption count="13" label="201704"/><FilterOption count="13" label="201706"/><FilterOption count="13" label="201901"/><FilterOption count="13" label="202002"/><FilterOption count="13" label="202104"/><FilterOption count="13" label="202109"/><FilterOption count="12" label="201006"/><FilterOption count="12" label="201111"/><FilterOption count="12" label="201406"/><FilterOption count="12" label="201407"/><FilterOption count="12" label="201502"/><FilterOption count="12" label="201607"/><FilterOption count="12" label="201709"/><FilterOption count="12" label="201712"/><FilterOption count="12" label="201807"/><FilterOption count="12" label="201809"/><FilterOption count="12" label="201811"/><FilterOption count="12" label="202005"/><FilterOption count="11" label="200912"/><FilterOption count="11" label="201112"/><FilterOption count="11" label="201204"/><FilterOption count="11" label="201305"/><FilterOption count="11" label="201307"/><FilterOption count="11" label="201503"/><FilterOption count="11" label="201506"/><FilterOption count="11" label="201602"/><FilterOption count="11" label="201609"/><FilterOption count="10" label="201207"/><FilterOption count="10" label="201212"/><FilterOption count="10" label="201301"/><FilterOption count="10" label="201302"/><FilterOption count="10" label="201304"/><FilterOption count="10" label="201311"/><FilterOption count="10" label="201312"/><FilterOption count="10" label="201404"/><FilterOption count="10" label="201408"/><FilterOption count="10" label="201411"/><FilterOption count="10" label="201801"/><FilterOption count="10" label="201808"/><FilterOption count="10" label="201903"/><FilterOption count="10" label="201904"/><FilterOption count="9" label="200811"/><FilterOption count="9" label="201007"/><FilterOption count="9" label="201205"/><FilterOption count="9" label="201209"/><FilterOption count="9" label="201303"/><FilterOption count="9" label="201510"/><FilterOption count="9" label="201511"/><FilterOption count="9" label="201608"/><FilterOption count="9" label="201802"/><FilterOption count="9" label="201804"/><FilterOption count="9" label="201806"/><FilterOption count="8" label="200805"/><FilterOption count="8" label="200807"/><FilterOption count="8" label="200812"/><FilterOption count="8" label="201001"/><FilterOption count="8" label="201011"/><FilterOption count="8" label="201101"/><FilterOption count="8" label="201107"/><FilterOption count="8" label="201308"/><FilterOption count="8" label="201410"/><FilterOption count="8" label="201701"/><FilterOption count="8" label="201702"/><FilterOption count="8" label="201703"/><FilterOption count="8" label="201805"/><FilterOption count="8" label="202010"/></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="2010" label="Spain"/><FilterOption id="DE" count="1210" label="Germany"/><FilterOption id="FR" count="1174" label="France"/><FilterOption id="IT" count="1149" label="Italy"/><FilterOption id="US" count="1137" label="US"/><FilterOption id="GB" count="1071" label="UK"/><FilterOption id="CA" count="904" label="Canada"/><FilterOption id="BE" count="884" label="Belgium"/><FilterOption id="PL" count="766" label="Poland"/><FilterOption id="AU" count="720" label="Australia"/><FilterOption id="NL" count="702" label="Netherlands"/><FilterOption id="AT" count="593" label="Austria"/><FilterOption id="CZ" count="582" label="Czech Republic"/><FilterOption id="RU" count="547" label="Russian Federation"/><FilterOption id="HU" count="528" label="Hungary"/><FilterOption id="SE" count="492" label="Sweden"/><FilterOption id="IL" count="490" label="Israel"/><FilterOption id="KR" count="454" label="South Korea"/><FilterOption id="CH" count="429" label="Switzerland"/><FilterOption id="BR" count="412" label="Brazil"/><FilterOption id="DK" count="407" label="Denmark"/><FilterOption id="AR" count="370" label="Argentina"/><FilterOption id="PT" count="363" label="Portugal"/><FilterOption id="GR" count="354" label="Greece"/><FilterOption id="MX" count="351" label="Mexico"/><FilterOption id="TW" count="344" label="Taiwan"/><FilterOption id="JP" count="306" label="Japan"/><FilterOption id="RO" count="298" label="Romania"/><FilterOption id="ZA" count="281" label="South Africa"/><FilterOption id="FI" count="279" label="Finland"/><FilterOption id="TR" count="259" label="Turkey"/><FilterOption id="NO" count="249" label="Norway"/><FilterOption id="BG" count="237" label="Bulgaria"/><FilterOption id="SK" count="236" label="Slovakia"/><FilterOption id="IE" count="217" label="Ireland"/><FilterOption id="NZ" count="206" label="New Zealand"/><FilterOption id="UA" count="206" label="Ukraine"/><FilterOption id="CL" count="204" label="Chile"/><FilterOption id="SG" count="192" label="Singapore"/><FilterOption id="CN" count="190" label="China"/><FilterOption id="HK" count="185" label="Hong Kong"/><FilterOption id="IN" count="160" label="India"/><FilterOption id="TH" count="153" label="Thailand"/><FilterOption id="CO" count="151" label="Colombia"/><FilterOption id="RS" count="148" label="Serbia"/><FilterOption id="PE" count="143" label="Peru"/><FilterOption id="PR" count="135" label="Puerto Rico"/><FilterOption id="LT" count="134" label="Lithuania"/><FilterOption id="HR" count="133" label="Croatia"/><FilterOption id="LV" count="128" label="Latvia"/><FilterOption id="EE" count="123" label="Estonia"/><FilterOption id="MY" count="115" label="Malaysia"/><FilterOption id="PH" count="73" label="Philippines"/><FilterOption id="X5" count="68" label="Europe"/><FilterOption id="SI" count="65" label="Slovenia"/><FilterOption id="EG" count="42" label="Egypt"/><FilterOption id="XD" count="35" label="North America"/><FilterOption id="BY" count="34" label="Belarus"/><FilterOption id="GE" count="33" label="Georgia"/><FilterOption id="PA" count="33" label="Panama"/><FilterOption id="SA" count="32" label="Saudi Arabia"/><FilterOption id="GT" count="31" label="Guatemala"/><FilterOption id="LB" count="31" label="Lebanon"/><FilterOption id="BA" count="30" label="Bosnia and Herzegovina"/><FilterOption id="CR" count="24" label="Costa Rica"/><FilterOption id="VN" count="24" label="Vietnam"/><FilterOption id="X2" count="22" label="Asia"/><FilterOption id="XE" count="18" label="South America"/><FilterOption id="LU" count="17" label="Luxembourg"/><FilterOption id="ID" count="15" label="Indonesia"/><FilterOption id="TN" count="15" label="Tunisia"/><FilterOption id="KP" count="14" label="North Korea"/><FilterOption id="EU" count="13" label="EU"/><FilterOption id="EC" count="12" label="Ecuador"/><FilterOption id="MA" count="12" label="Morocco"/><FilterOption id="MK" count="11" label="Macedonia, The Former Yugoslav Republic of"/><FilterOption id="PK" count="11" label="Pakistan"/><FilterOption id="JO" count="10" label="Jordan"/><FilterOption id="VE" count="10" label="Venezuela"/><FilterOption id="DO" count="9" label="Dominican Republic"/><FilterOption id="IS" count="9" label="Iceland"/><FilterOption id="AE" count="9" label="United Arab Emirates"/><FilterOption id="DZ" count="7" label="Algeria"/><FilterOption id="KW" count="7" label="Kuwait"/><FilterOption id="UY" count="6" label="Uruguay"/><FilterOption id="AL" count="5" label="Albania"/><FilterOption id="AS" count="5" label="American Samoa"/><FilterOption id="KZ" count="5" label="Kazakhstan"/><FilterOption id="AD" count="4" label="Andorra"/><FilterOption id="MC" count="4" label="Monaco"/><FilterOption id="ME" count="4" label="Montenegro"/><FilterOption id="OM" count="4" label="Oman"/><FilterOption id="XW" count="4" label="Western Europe"/><FilterOption id="X0" count="3" label="Africa"/><FilterOption id="BS" count="3" label="Bahamas"/><FilterOption id="MT" count="3" label="Malta"/><FilterOption id="MD" count="3" label="Moldova, Republic of"/><FilterOption id="QA" count="3" label="Qatar"/><FilterOption id="LK" count="3" label="Sri Lanka"/><FilterOption id="X1" count="2" label="Americas"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="17"><FilterOption id="EAMAA" count="1937" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAYAD" count="1889" label="Young Adults (18-44 yrs)"/><FilterOption id="EAAAD" count="1880" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAELD" count="1607" label="Elderly Adults (80 and over)"/><FilterOption id="EGFEM" count="136" label="Female"/><FilterOption id="EAADL" count="118" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="83" label="Children (6-12 yrs)"/><FilterOption id="EGMAL" count="60" label="Male"/><FilterOption id="EVHVA" count="55" label="Healthy volunteers accepted"/><FilterOption id="EAPRE" count="22" label="Preschool Children (2-5 yrs)"/><FilterOption id="ECASI" count="19" label="Asian Ancestry"/><FilterOption id="ECJAP" count="18" label="Japanese Ancestry"/><FilterOption id="EAINF" count="13" label="Infants (6-23 months)"/><FilterOption id="EANEW" count="11" label="Newborn Infants (up to 5 months)"/><FilterOption id="ECAFR" count="5" label="African Ancestry"/><FilterOption id="EVHVO" count="5" label="Healthy volunteers only"/><FilterOption id="ECEUR" count="4" label="European Ancestry"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="26"><FilterOption id="SSTINV" count="1895" label="Interventional"/><FilterOption id="SIPTRE" count="1742" label="Treatment"/><FilterOption id="SIARND" count="1435" label="Randomized"/><FilterOption id="SISPRL" count="1422" label="Parallel Assignment"/><FilterOption id="SIMOPN" count="986" label="Open Label"/><FilterOption id="SIMMBD" count="838" label="Multiple Blind"/><FilterOption id="SICPLC" count="774" label="Placebo Control"/><FilterOption id="SICACT" count="471" label="Active Control"/><FilterOption id="SISSNG" count="388" label="Single Group Assignment"/><FilterOption id="SIANON" count="343" label="Non-Randomized"/><FilterOption id="SICNOC" count="262" label="No Control"/><FilterOption id="SIPPRE" count="132" label="Prevention"/><FilterOption id="SSTOBS" count="121" label="Observational"/><FilterOption id="SOTPRO" count="93" label="Prospective"/><FilterOption id="SOSCOH" count="78" label="Cohort"/><FilterOption id="SIMSBD" count="62" label="Single Blind"/><FilterOption id="SISXOV" count="40" label="Crossover Assignment"/><FilterOption id="SOTRET" count="24" label="Retrospective"/><FilterOption id="SIPDIA" count="17" label="Diagnosis"/><FilterOption id="SOSCSC" count="10" label="Case Control"/><FilterOption id="SODXSC" count="10" label="Cross-sectional"/><FilterOption id="SODLNG" count="7" label="Longitudinal"/><FilterOption id="SICDSC" count="4" label="Dose Comparison"/><FilterOption id="SISFCT" count="4" label="Factorial Assignment"/><FilterOption id="SISEAA" count="2" label="Expanded Access Assignment"/><FilterOption id="SICHST" count="1" label="Historical Control"/></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="1323" label="ClinicalTrials.gov and others"/><FilterOption id="CTGOV" count="668" label="ClinicalTrials.gov only"/><FilterOption id="OTHERS" count="14" label="Others only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="757" label="Anticancer"/><FilterOption id="2953" count="485" label="Anti-inflammatory"/><FilterOption id="55685" count="365" label="Anticancer monoclonal antibody"/><FilterOption id="62255" count="337" label="Anticancer protein kinase inhibitor"/><FilterOption id="991" count="291" label="Antiviral"/><FilterOption id="1589" count="251" label="Apoptosis stimulator"/><FilterOption id="61" count="194" label="Angiogenesis inhibitor"/><FilterOption id="767" count="194" label="Cell cycle inhibitor"/><FilterOption id="7293" count="180" label="Synergist"/><FilterOption id="393" count="166" label="Immunostimulant"/><FilterOption id="7761" count="157" label="T-lymphocyte stimulator"/><FilterOption id="1596" count="107" label="Immunomodulator"/><FilterOption id="50" count="102" label="Anticancer alkylating agent"/><FilterOption id="140" count="102" label="DNA synthesis inhibitor"/><FilterOption id="1569" count="94" label="Anticancer antimetabolite"/><FilterOption id="2657" count="93" label="Antihypertensive"/><FilterOption id="396" count="89" label="Immunosuppressant"/><FilterOption id="15184" count="75" label="Systemic antipsoriatic product"/><FilterOption id="2946" count="70" label="Analgesic"/><FilterOption id="399" count="69" label="Hypoglycemic agent"/><FilterOption id="1615" count="63" label="Neuroprotectant"/><FilterOption id="2575" count="59" label="Microtubule inhibitor"/><FilterOption id="2576" count="57" label="Microtubule stabilizer"/><FilterOption id="2660" count="51" label="Vasoprotectant"/><FilterOption id="747" count="48" label="HIV replication inhibitor"/><FilterOption id="1594" count="45" label="Antibacterial"/><FilterOption id="2947" count="45" label="Antiparkinsonian"/><FilterOption id="70" count="44" label="Anticonvulsant agent"/><FilterOption id="382" count="44" label="TNF alpha synthesis inhibitor"/><FilterOption id="388" count="41" label="Vasodilator"/><FilterOption id="659" count="36" label="Coagulation inhibitor"/><FilterOption id="12379" count="36" label="Therapeutic vaccine"/><FilterOption id="646" count="35" label="Bronchodilator"/><FilterOption id="449" count="32" label="Antiarrhythmic agent"/><FilterOption id="695" count="32" label="Metastasis inhibitor"/><FilterOption id="2659" count="31" label="Cardioprotectant"/><FilterOption id="2667" count="29" label="Antiarteriosclerotic"/><FilterOption id="2941" count="29" label="Antidepressant"/><FilterOption id="2943" count="29" label="Antipsychotic"/><FilterOption id="610" count="29" label="Hematopoietic stimulator"/><FilterOption id="284" count="29" label="Nootropic agent"/><FilterOption id="71" count="28" label="Antihypercholesterolemic agent"/><FilterOption id="664" count="28" label="Fibrosuppressant"/><FilterOption id="7760" count="25" label="T-lymphocyte inhibitor"/><FilterOption id="750" count="24" label="DNA intercalator"/><FilterOption id="62254" count="22" label="Anticancer hormone antagonist"/><FilterOption id="539" count="21" label="Immunotoxin"/><FilterOption id="15187" count="21" label="Systemic dermatological antibacterial product"/><FilterOption id="12378" count="20" label="Prophylactic vaccine"/><FilterOption id="1332" count="19" label="Gastrointestinal system agent"/><FilterOption id="312" count="19" label="Platelet aggregation inhibitor"/><FilterOption id="12372" count="18" label="Protein subunit vaccine"/><FilterOption id="1470" count="18" label="Respiratory system agent"/><FilterOption id="805" count="17" label="Folate modulator"/><FilterOption id="439" count="17" label="RNA synthesis inhibitor"/><FilterOption id="55684" count="16" label="Anticancer antibody"/><FilterOption id="59620" count="16" label="Unspecified drug target"/><FilterOption id="72" count="15" label="Antihyperlipidemic agent"/><FilterOption id="5580" count="14" label="Chemotaxis inhibitor"/><FilterOption id="5704" count="13" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="13" label="B-lymphocyte migration inhibitor"/><FilterOption id="1538" count="13" label="Bacterial protein synthesis inhibitor"/><FilterOption id="32411" count="13" label="Hepatitis B virus replication inhibitor"/><FilterOption id="3980" count="13" label="HIV fusion inhibitor"/><FilterOption id="2942" count="12" label="Anxiolytic"/><FilterOption id="104" count="12" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="1748" count="12" label="Fungicide"/><FilterOption id="463" count="12" label="Ribosome binding agent"/><FilterOption id="937" count="11" label="Androgen synthesis inhibitor"/><FilterOption id="3984" count="11" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="38206" count="11" label="Biguanide antidiabetic product"/><FilterOption id="339" count="11" label="Protein synthesis inhibitor"/><FilterOption id="1532" count="11" label="Viral replication inhibitor"/><FilterOption id="7018" count="10" label="Antihypertriglyceridemic agent"/><FilterOption id="7294" count="10" label="Antisense oligonucleotide inhibitor"/><FilterOption id="89" count="10" label="Bone resorption inhibitor"/><FilterOption id="3189" count="10" label="Corticosteroid agonist"/><FilterOption id="15148" count="10" label="Ocular antineovascularisation agent"/><FilterOption id="12370" count="10" label="Recombinant viral vector vaccine"/><FilterOption id="2954" count="10" label="Steroidal anti-inflammatory"/><FilterOption id="966" count="9" label="Cardiac agent"/><FilterOption id="2955" count="9" label="Non-steroidal anti-inflammatory"/><FilterOption id="285" count="9" label="Norepinephrine uptake inhibitor"/><FilterOption id="882" count="8" label="5-HETE modulator"/><FilterOption id="524" count="8" label="Adjuvant"/><FilterOption id="1590" count="8" label="Apoptosis inhibitor"/><FilterOption id="12364" count="8" label="Live attenuated viral vaccine"/><FilterOption id="7292" count="8" label="Vulnerary agent"/><FilterOption id="2970" count="7" label="Anti-emetic"/><FilterOption id="74" count="7" label="Antioxidant agent"/><FilterOption id="863" count="7" label="Bile acid modulator"/><FilterOption id="1537" count="7" label="Cephalosporin"/><FilterOption id="7211" count="7" label="CNS diagnostic agent"/><FilterOption id="137" count="7" label="Diuretic agent"/><FilterOption id="161" count="7" label="Ergosterol synthesis inhibitor"/><FilterOption id="38212" count="7" label="Human insulin intermediate acting product"/><FilterOption id="1540" count="7" label="Macrolide antibiotic"/><FilterOption id="15178" count="7" label="Systemic dermatological antifungal product"/><FilterOption id="527" count="6" label="Bone synthesis inhibitor"/><FilterOption id="965" count="6" label="Cardiovascular agent"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="531" label="Unspecified"/><FilterOption id="YES" count="382" label="Yes"/><FilterOption id="NO" count="175" label="No"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="67" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8719" count="59" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="9218" count="57" label="HIV infection - Assessment of Immune Response"/><FilterOption id="9215" count="54" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="9247" count="54" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8738" count="49" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="7879" count="49" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="8489" count="48" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8998" count="47" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8481" count="47" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9213" count="46" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="6919" count="44" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="6940" count="43" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="8713" count="42" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7538" count="42" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8721" count="41" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="6924" count="40" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7354" count="38" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8078" count="37" label="Leukemia - Assessment of adverse events"/><FilterOption id="8720" count="36" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8522" count="36" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="8663" count="35" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8722" count="34" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="7908" count="34" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9153" count="31" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7027" count="31" label="Melanoma - Assessment of adverse events"/><FilterOption id="8639" count="29" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="7611" count="29" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="6951" count="29" label="Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="9242" count="28" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7891" count="28" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8505" count="28" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7680" count="28" label="Lymphoma - Assessment of adverse events"/><FilterOption id="9238" count="27" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="7898" count="27" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7547" count="26" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7393" count="26" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8996" count="25" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="8430" count="25" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7360" count="25" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7367" count="25" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="9122" count="24" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7909" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8514" count="24" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7563" count="24" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8725" count="23" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="7489" count="23" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="2622" count="22" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="22595" count="22" label="End stage renal disease - Assessment of adverse events"/><FilterOption id="8077" count="22" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="8640" count="22" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7569" count="22" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7045" count="22" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7190" count="22" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="11728" count="21" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8999" count="21" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8759" count="21" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8151" count="21" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9300" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8513" count="21" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7679" count="21" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="6944" count="21" label="Melanoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7372" count="21" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8744" count="20" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8187" count="20" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="9255" count="20" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="7907" count="20" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="10828" count="20" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="2492" count="19" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="9212" count="19" label="HIV infection - Assessment of Viral Load"/><FilterOption id="7373" count="19" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="11717" count="18" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="8451" count="18" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="2623" count="18" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="9197" count="18" label="HIV infection - Assessment of virological response - Assessment of virological failure"/><FilterOption id="7049" count="18" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15312" count="18" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="11780" count="17" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8163" count="17" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8519" count="17" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"/><FilterOption id="7520" count="17" label="Multiple myeloma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="25660" count="17" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="17220" count="16" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="11735" count="16" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="37159" count="16" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8754" count="16" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8189" count="16" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="6863" count="16" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="7988" count="16" label="Leukemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8508" count="16" label="Lung tumor - Assessment of Overall Response"/><FilterOption id="26033" count="16" label="Pain - Assessment of adverse events"/><FilterOption id="10545" count="16" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15212" count="16" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="15907" count="16" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="17356" count="15" label="Anemia - Assessment of adverse events"/><FilterOption id="2703" count="15" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="12115" count="15" label="Hepatobiliary system tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="12064" count="15" label="Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of disease control rate"/><FilterOption id="7916" count="15" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="7558" count="15" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="226" label="Alanine transaminase"/><FilterOption id="2527" count="193" label="Aspartate aminotransferase"/><FilterOption id="213" count="171" label="Creatinine"/><FilterOption id="1236" count="158" label="Hemoglobin"/><FilterOption id="2054" count="149" label="Blood platelets"/><FilterOption id="12058" count="147" label="Total body mass"/><FilterOption id="2387" count="127" label="Bilirubin"/><FilterOption id="1925" count="125" label="Neutrophils"/><FilterOption id="1904" count="115" label="Heart rate"/><FilterOption id="46" count="114" label="C-reactive protein"/><FilterOption id="1735" count="113" label="Glucose"/><FilterOption id="3" count="106" label="HER2"/><FilterOption id="125" count="99" label="Leukocyte count"/><FilterOption id="1857" count="97" label="T-cell surface glycoprotein CD4"/><FilterOption id="330" count="96" label="Systolic blood pressure"/><FilterOption id="28899" count="95" label="Alkaline phosphatase"/><FilterOption id="133" count="95" label="Total cholesterol"/><FilterOption id="217" count="95" label="Triglycerides"/><FilterOption id="152" count="92" label="Low-density lipoprotein cholesterol"/><FilterOption id="2586" count="87" label="Blood pressure"/><FilterOption id="118" count="84" label="Albumin"/><FilterOption id="153" count="81" label="High-density lipoprotein cholesterol"/><FilterOption id="4806" count="81" label="Lymphocytes"/><FilterOption id="332" count="79" label="Diastolic blood pressure"/><FilterOption id="7895" count="76" label="Estimated glomerular filtration rate"/><FilterOption id="1880" count="72" label="T-Helper Lymphocytes"/><FilterOption id="824" count="71" label="Programmed cell death 1 ligand 1"/><FilterOption id="5" count="65" label="Estrogen receptor"/><FilterOption id="3447" count="64" label="T-cell surface glycoprotein CD8 alpha chain"/><FilterOption id="289" count="63" label="Hemoglobin A, glycosylated"/><FilterOption id="44218" count="61" label="Human immunodeficiency virus RNA"/><FilterOption id="8458" count="60" label="gamma-Glutamyltransferase"/><FilterOption id="2417" count="59" label="Calcium"/><FilterOption id="8" count="59" label="Epidermal growth factor receptor"/><FilterOption id="2098" count="59" label="Potassium"/><FilterOption id="82" count="58" label="B-Raf proto-oncogene serine/threonine-protein kinase"/><FilterOption id="14767" count="56" label="Lipids"/><FilterOption id="176" count="55" label="Interleukin-6"/><FilterOption id="8024" count="54" label="Creatine kinase"/><FilterOption id="2662" count="54" label="Sodium"/><FilterOption id="4522" count="53" label="Erythrocytes"/><FilterOption id="46505" count="52" label="Cytotoxic T-Lymphocytes"/><FilterOption id="6" count="51" label="Progesterone receptor"/><FilterOption id="147" count="50" label="Six-minute walk distance"/><FilterOption id="248" count="49" label="Eosinophils"/><FilterOption id="106" count="47" label="N-terminal Pro Brain Natriuretic Peptide"/><FilterOption id="113" count="45" label="Body Mass Index"/><FilterOption id="2713" count="44" label="Forced expiratory volume"/><FilterOption id="38" count="44" label="Prostate-specific antigen"/><FilterOption id="148" count="44" label="QT interval"/><FilterOption id="44216" count="43" label="Body temperature"/><FilterOption id="154" count="42" label="Lactate dehydrogenase"/><FilterOption id="36136" count="38" label="Cytokines"/><FilterOption id="1221" count="38" label="Hematocrit"/><FilterOption id="7033" count="38" label="Lipase"/><FilterOption id="2358" count="35" label="Urea nitrogen"/><FilterOption id="46506" count="33" label="T-Lymphocytes"/><FilterOption id="9807" count="31" label="Basophils"/><FilterOption id="8097" count="31" label="Monocytes"/><FilterOption id="11857" count="31" label="Transaminases"/><FilterOption id="1912" count="30" label="Forced Vital Capacity"/><FilterOption id="274" count="30" label="Tumor necrosis factor"/><FilterOption id="3374" count="29" label="Bone mineral density"/><FilterOption id="1183" count="29" label="Urinary albumin to creatinine ratio"/><FilterOption id="2382" count="28" label="Phosphorus"/><FilterOption id="12516" count="28" label="Urinary protein"/><FilterOption id="52" count="27" label="GTPase KRas"/><FilterOption id="1945" count="27" label="Left ventricular ejection fraction"/><FilterOption id="6663" count="26" label="B-lymphocytes"/><FilterOption id="2626" count="26" label="Total protein"/><FilterOption id="1731" count="25" label="B-lymphocyte antigen CD20"/><FilterOption id="808" count="25" label="Insulin"/><FilterOption id="252" count="24" label="Interferon gamma"/><FilterOption id="6993" count="23" label="Alpha-amylase 1"/><FilterOption id="126" count="23" label="BCR-ABL1 fusion protein"/><FilterOption id="11114" count="23" label="Brain"/><FilterOption id="9" count="23" label="Cellular tumor antigen p53"/><FilterOption id="3451" count="23" label="Immunoglobulin G"/><FilterOption id="1289" count="23" label="Tumor mass"/><FilterOption id="7" count="22" label="Antigen KI-67"/><FilterOption id="165" count="22" label="Beta-2-microglobulin"/><FilterOption id="3247" count="22" label="Chlorides"/><FilterOption id="30214" count="22" label="Joint swelling"/><FilterOption id="30217" count="22" label="Joint tenderness"/><FilterOption id="2053" count="22" label="Non-high density lipoprotein cholesterol"/><FilterOption id="92" count="22" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"/><FilterOption id="18315" count="22" label="Visual acuity"/><FilterOption id="5700" count="21" label="ALK receptor"/><FilterOption id="215" count="21" label="Apolipoprotein B-100"/><FilterOption id="2515" count="21" label="Magnesium"/><FilterOption id="3083" count="21" label="Phosphate"/><FilterOption id="288" count="21" label="Uric acid"/><FilterOption id="781" count="20" label="Erythrocyte sedimentation rate"/><FilterOption id="749" count="20" label="Free light chains"/><FilterOption id="13158" count="20" label="Myeloma protein"/><FilterOption id="10260" count="20" label="Respiratory frequency"/><FilterOption id="22" count="19" label="Breast cancer type 1 susceptibility protein"/><FilterOption id="44186" count="19" label="Hepatitis C virus RNA"/><FilterOption id="2411" count="19" label="Pulmonary vascular resistance"/><FilterOption id="41" count="18" label="Breast cancer type 2 susceptibility protein"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="6"><FilterOption id="SIEEFC" count="1867" label="Efficacy"/><FilterOption id="SIESFT" count="1805" label="Safety"/><FilterOption id="SIEPCK" count="812" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="466" label="Pharmacodynamics"/><FilterOption id="SIEBAV" count="5" label="Bioavailability"/><FilterOption id="SIEBEQ" count="1" label="Bioequivalence"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="46" label="paclitaxel"/><FilterOption id="44383" count="43" label="carboplatin"/><FilterOption id="3199" count="36" label="gemcitabine"/><FilterOption id="6736" count="31" label="rituximab"/><FilterOption id="8047" count="30" label="bevacizumab"/><FilterOption id="2953" count="29" label="docetaxel"/><FilterOption id="72699" count="26" label="atezolizumab"/><FilterOption id="15954" count="25" label="bortezomib"/><FilterOption id="6386" count="24" label="trastuzumab"/><FilterOption id="54804" count="23" label="nivolumab"/><FilterOption id="7310" count="22" label="ritonavir"/><FilterOption id="27572" count="21" label="lenalidomide"/><FilterOption id="3792" count="20" label="oxaliplatin"/><FilterOption id="12205" count="17" label="capecitabine"/><FilterOption id="36630" count="17" label="ipilimumab"/><FilterOption id="70667" count="17" label="pembrolizumab"/><FilterOption id="2784" count="16" label="letrozole"/><FilterOption id="3536" count="16" label="pemetrexed disodium"/><FilterOption id="13340" count="15" label="everolimus"/><FilterOption id="5369" count="15" label="ribavirin"/><FilterOption id="14681" count="14" label="lopinavir + ritonavir"/><FilterOption id="47000" count="13" label="bendamustine"/><FilterOption id="3072" count="13" label="etoposide phosphate"/><FilterOption id="3313" count="13" label="fulvestrant"/><FilterOption id="81193" count="12" label="durvalumab"/><FilterOption id="11961" count="12" label="erlotinib"/><FilterOption id="3474" count="12" label="lamivudine"/><FilterOption id="54488" count="12" label="raltegravir"/><FilterOption id="10309" count="11" label="abiraterone"/><FilterOption id="54601" count="11" label="carfilzomib"/><FilterOption id="3081" count="11" label="exemestane"/><FilterOption id="6156" count="11" label="fludarabine"/><FilterOption id="3669" count="11" label="mycophenolate mofetil"/><FilterOption id="53227" count="11" label="obinutuzumab"/><FilterOption id="23625" count="11" label="peginterferon alfa-2a"/><FilterOption id="4510" count="11" label="tacrolimus"/><FilterOption id="15254" count="10" label="atazanavir"/><FilterOption id="55237" count="10" label="ibrutinib"/><FilterOption id="6050" count="10" label="metformin hydrochloride"/><FilterOption id="28532" count="10" label="pertuzumab"/><FilterOption id="49219" count="10" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="14493" count="10" label="tenofovir disoproxil fumarate"/><FilterOption id="55288" count="10" label="trametinib"/><FilterOption id="56544" count="9" label="cobimetinib"/><FilterOption id="32981" count="9" label="darunavir"/><FilterOption id="2871" count="9" label="irinotecan"/><FilterOption id="29016" count="9" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="37370" count="8" label="azacitidine"/><FilterOption id="10388" count="8" label="cetuximab"/><FilterOption id="5999" count="8" label="ciclosporin, Novartis"/><FilterOption id="53133" count="8" label="dabrafenib"/><FilterOption id="53200" count="8" label="daratumumab"/><FilterOption id="10172" count="8" label="efavirenz"/><FilterOption id="4728" count="8" label="emtricitabine"/><FilterOption id="11519" count="8" label="mitoxantrone"/><FilterOption id="96193" count="8" label="spartalizumab"/><FilterOption id="45562" count="8" label="tremelimumab"/><FilterOption id="61901" count="7" label="buparlisib"/><FilterOption id="2836" count="7" label="clopidogrel"/><FilterOption id="59062" count="7" label="dolutegravir"/><FilterOption id="48181" count="7" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="29831" count="7" label="sorafenib"/><FilterOption id="54469" count="7" label="vemurafenib"/><FilterOption id="6242" count="6" label="abacavir"/><FilterOption id="3321" count="6" label="anastrozole"/><FilterOption id="55305" count="6" label="binimetinib"/><FilterOption id="33591" count="6" label="lapatinib"/><FilterOption id="45841" count="6" label="lenvatinib mesylate"/><FilterOption id="37613" count="6" label="maraviroc"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="27696" count="6" label="pomalidomide"/><FilterOption id="65360" count="6" label="ribociclib"/><FilterOption id="70895" count="6" label="venetoclax"/><FilterOption id="65353" count="5" label="alpelisib"/><FilterOption id="2807" count="5" label="atorvastatin"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="44314" count="5" label="tamoxifen"/><FilterOption id="4529" count="5" label="temozolomide"/><FilterOption id="12150" count="5" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="72538" count="4" label="abemaciclib"/><FilterOption id="39518" count="4" label="albiglutide"/><FilterOption id="11141" count="4" label="basiliximab"/><FilterOption id="13239" count="4" label="decitabine"/><FilterOption id="73843" count="4" label="encorafenib"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="59460" count="4" label="isatuximab"/><FilterOption id="16063" count="4" label="olaparib"/><FilterOption id="46018" count="4" label="onartuzumab"/><FilterOption id="10271" count="4" label="palbociclib"/><FilterOption id="71886" count="4" label="ribavirin (oral tablet, HCV), Roche"/><FilterOption id="44313" count="4" label="simvastatin"/><FilterOption id="4200" count="4" label="sirolimus"/><FilterOption id="70678" count="4" label="xentuzumab"/><FilterOption id="14163" count="3" label="adalimumab"/><FilterOption id="50935" count="3" label="cabozantinib S-malate"/><FilterOption id="59953" count="3" label="capmatinib"/><FilterOption id="44384" count="3" label="ceftriaxone"/><FilterOption id="64948" count="3" label="dupilumab"/><FilterOption id="56518" count="3" label="elotuzumab"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="821" label="Other Publications"/><FilterOption id="PR" count="771" label="Press Releases"/><FilterOption id="SERIAL" count="735" label="Serial Publications"/><FilterOption id="CORPORATE" count="210" label="Corporate Publications"/><FilterOption id="CONFERENCE" count="165" label="Conference Reports"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="54804" count="16" label="nivolumab"/><FilterOption id="32677" count="14" label="rivaroxaban"/><FilterOption id="14163" count="12" label="adalimumab"/><FilterOption id="27572" count="12" label="lenalidomide"/><FilterOption id="72699" count="11" label="atezolizumab"/><FilterOption id="81193" count="11" label="durvalumab"/><FilterOption id="45499" count="11" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="55275" count="10" label="secukinumab"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="11961" count="8" label="erlotinib"/><FilterOption id="14681" count="8" label="lopinavir + ritonavir"/><FilterOption id="35644" count="8" label="methoxy polyethylene glycol-epoetin beta"/><FilterOption id="70667" count="8" label="pembrolizumab"/><FilterOption id="17814" count="8" label="pregabalin"/><FilterOption id="57369" count="7" label="etrolizumab"/><FilterOption id="65240" count="7" label="evolocumab"/><FilterOption id="52854" count="7" label="macitentan"/><FilterOption id="12037" count="7" label="mepolizumab"/><FilterOption id="16063" count="7" label="olaparib"/><FilterOption id="54488" count="7" label="raltegravir"/><FilterOption id="54614" count="7" label="riociguat"/><FilterOption id="6736" count="7" label="rituximab"/><FilterOption id="13340" count="6" label="everolimus"/><FilterOption id="55237" count="6" label="ibrutinib"/><FilterOption id="36630" count="6" label="ipilimumab"/><FilterOption id="12978" count="6" label="moxifloxacin"/><FilterOption id="51388" count="6" label="nilotinib"/><FilterOption id="77337" count="6" label="risankizumab"/><FilterOption id="6259" count="6" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="74726" count="6" label="upadacitinib"/><FilterOption id="53547" count="5" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="18425" count="5" label="ambrisentan"/><FilterOption id="52967" count="5" label="apixaban"/><FilterOption id="7781" count="5" label="aripiprazole"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="5871" count="5" label="bosentan"/><FilterOption id="30379" count="5" label="bosutinib"/><FilterOption id="37613" count="5" label="maraviroc"/><FilterOption id="53172" count="5" label="mavoglurant"/><FilterOption id="3700" count="5" label="nevirapine"/><FilterOption id="50963" count="5" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"/><FilterOption id="43738" count="5" label="pazopanib"/><FilterOption id="8713" count="5" label="sildenafil citrate"/><FilterOption id="4200" count="5" label="sirolimus"/><FilterOption id="29831" count="5" label="sorafenib"/><FilterOption id="50040" count="5" label="tacrolimus (oral sustained-release), Astellas"/><FilterOption id="45562" count="5" label="tremelimumab"/><FilterOption id="100097" count="4" label="bictegravir + emtricitabine + tenofovir alafenamide (HIV-1 infection), Gilead"/><FilterOption id="53133" count="4" label="dabrafenib"/><FilterOption id="59062" count="4" label="dolutegravir"/><FilterOption id="15593" count="4" label="eculizumab"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="4567" count="4" label="etanercept"/><FilterOption id="10154" count="4" label="fingolimod"/><FilterOption id="3199" count="4" label="gemcitabine"/><FilterOption id="11460" count="4" label="imatinib"/><FilterOption id="19462" count="4" label="micafungin"/><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"/><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"/><FilterOption id="46613" count="4" label="tralokinumab"/><FilterOption id="8714" count="4" label="voriconazole"/><FilterOption id="72538" count="3" label="abemaciclib"/><FilterOption id="39518" count="3" label="albiglutide"/><FilterOption id="69066" count="3" label="alectinib"/><FilterOption id="44374" count="3" label="amiodarone"/><FilterOption id="64328" count="3" label="aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck"/><FilterOption id="15254" count="3" label="atazanavir"/><FilterOption id="59098" count="3" label="baricitinib"/><FilterOption id="31831" count="3" label="belimumab"/><FilterOption id="72743" count="3" label="birtamimab"/><FilterOption id="12135" count="3" label="celecoxib"/><FilterOption id="64775" count="3" label="etelcalcetide (secondary hyperparathyroidism), Ono/Amgen"/><FilterOption id="56516" count="3" label="fedratinib"/><FilterOption id="53840" count="3" label="gantenerumab"/><FilterOption id="6850" count="3" label="infliximab"/><FilterOption id="6692" count="3" label="natalizumab"/><FilterOption id="40115" count="3" label="radium Ra 223 dichloride"/><FilterOption id="54624" count="3" label="regorafenib"/><FilterOption id="54662" count="3" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"/><FilterOption id="56776" count="3" label="SHP-647"/><FilterOption id="12973" count="3" label="sunitinib"/><FilterOption id="4529" count="3" label="temozolomide"/><FilterOption id="50038" count="3" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"/><FilterOption id="6386" count="3" label="trastuzumab"/><FilterOption id="98615" count="3" label="trastuzumab deruxtecan"/><FilterOption id="21994" count="3" label="vardenafil hydrochloride"/><FilterOption id="2888" count="2" label="abatacept"/><FilterOption id="7982" count="2" label="abetimus"/><FilterOption id="50961" count="2" label="abobotulinumtoxinA"/><FilterOption id="84728" count="2" label="abrocitinib"/><FilterOption id="64893" count="2" label="acetylsalicylic acid + simvastatin + ramipril (oral, cardiovascular disease), Ferrer Internacional"/><FilterOption id="31012" count="2" label="aclidinium bromide"/><FilterOption id="6306" count="2" label="aldesleukin"/><FilterOption id="6893" count="2" label="alteplase"/><FilterOption id="69001" count="2" label="amantadine (extended release formulation, Parkinsons disease/movement disorder), Adamas"/><FilterOption id="2807" count="2" label="atorvastatin"/><FilterOption id="39209" count="2" label="axitinib"/><FilterOption id="37370" count="2" label="azacitidine"/><FilterOption id="7797" count="2" label="azimilide"/><FilterOption id="46721" count="2" label="benralizumab"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="27" label="carboplatin"/><FilterOption id="3803" count="22" label="paclitaxel"/><FilterOption id="3199" count="19" label="gemcitabine"/><FilterOption id="2953" count="15" label="docetaxel"/><FilterOption id="49219" count="15" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="6736" count="14" label="rituximab"/><FilterOption id="7310" count="13" label="ritonavir"/><FilterOption id="6386" count="12" label="trastuzumab"/><FilterOption id="12205" count="10" label="capecitabine"/><FilterOption id="3792" count="10" label="oxaliplatin"/><FilterOption id="15954" count="9" label="bortezomib"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="3536" count="8" label="pemetrexed disodium"/><FilterOption id="10309" count="7" label="abiraterone"/><FilterOption id="15254" count="7" label="atazanavir"/><FilterOption id="32981" count="7" label="darunavir"/><FilterOption id="3072" count="7" label="etoposide phosphate"/><FilterOption id="48181" count="6" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="27572" count="6" label="lenalidomide"/><FilterOption id="14681" count="6" label="lopinavir + ritonavir"/><FilterOption id="3669" count="6" label="mycophenolate mofetil"/><FilterOption id="47000" count="5" label="bendamustine"/><FilterOption id="2836" count="5" label="clopidogrel"/><FilterOption id="10172" count="5" label="efavirenz"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="6050" count="5" label="metformin hydrochloride"/><FilterOption id="5369" count="5" label="ribavirin"/><FilterOption id="4510" count="5" label="tacrolimus"/><FilterOption id="44375" count="5" label="warfarin"/><FilterOption id="54601" count="4" label="carfilzomib"/><FilterOption id="10388" count="4" label="cetuximab"/><FilterOption id="3081" count="4" label="exemestane"/><FilterOption id="10252" count="4" label="insulin glargine"/><FilterOption id="11519" count="4" label="mitoxantrone"/><FilterOption id="23625" count="4" label="peginterferon alfa-2a"/><FilterOption id="54488" count="4" label="raltegravir"/><FilterOption id="14493" count="4" label="tenofovir disoproxil fumarate"/><FilterOption id="12150" count="4" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="37370" count="3" label="azacitidine"/><FilterOption id="44384" count="3" label="ceftriaxone"/><FilterOption id="5999" count="3" label="ciclosporin, Novartis"/><FilterOption id="59062" count="3" label="dolutegravir"/><FilterOption id="7934" count="3" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="13928" count="3" label="enoxaparin sodium"/><FilterOption id="25880" count="3" label="enteric-coated mycophenolate sodium, Novartis"/><FilterOption id="13340" count="3" label="everolimus"/><FilterOption id="6156" count="3" label="fludarabine"/><FilterOption id="8832" count="3" label="glimepiride"/><FilterOption id="3353" count="3" label="insulin lispro"/><FilterOption id="33591" count="3" label="lapatinib"/><FilterOption id="54804" count="3" label="nivolumab"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="29016" count="3" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="72699" count="2" label="atezolizumab"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="72148" count="2" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="3130" count="2" label="filgrastim"/><FilterOption id="24471" count="2" label="fosamprenavir"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="3700" count="2" label="nevirapine"/><FilterOption id="28532" count="2" label="pertuzumab"/><FilterOption id="4196" count="2" label="ramipril"/><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"/><FilterOption id="4259" count="2" label="saquinavir"/><FilterOption id="44313" count="2" label="simvastatin"/><FilterOption id="44499" count="2" label="sitagliptin"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="15130" count="2" label="vinflunine"/><FilterOption id="6242" count="1" label="abacavir"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="2500" count="1" label="amlodipine"/><FilterOption id="7867" count="1" label="amprenavir"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="44281" count="1" label="betamethasone"/><FilterOption id="5957" count="1" label="budesonide (inhaled formulations), AstraZeneca"/><FilterOption id="12242" count="1" label="calcipotriol"/><FilterOption id="16915" count="1" label="calcium levofolinate"/><FilterOption id="12544" count="1" label="caspofungin"/><FilterOption id="2829" count="1" label="clarithromycin"/><FilterOption id="44370" count="1" label="clindamycin"/><FilterOption id="9049" count="1" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="53133" count="1" label="dabrafenib"/><FilterOption id="13239" count="1" label="decitabine"/><FilterOption id="2935" count="1" label="didanosine"/><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="3359" count="1" label="eptifibatide"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="11961" count="1" label="erlotinib"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="59060" count="1" label="fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline"/><FilterOption id="14336" count="1" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"/></Filter><Filter label="Trial Category" name="trialCategory" total="16"><FilterOption id="4" count="1393" label="Small molecule"/><FilterOption id="3" count="739" label="Biological"/><FilterOption id="8" count="130" label="Medical device"/><FilterOption id="9" count="71" label="Medical procedure"/><FilterOption id="5" count="57" label="Vaccine"/><FilterOption id="16" count="44" label="Behavioral intervention"/><FilterOption id="15" count="32" label="Radiation therapy"/><FilterOption id="11" count="31" label="Dietary supplement"/><FilterOption id="7" count="29" label="Gene therapy"/><FilterOption id="6" count="23" label="Cell therapy"/><FilterOption id="14" count="13" label="Diagnostic"/><FilterOption id="18" count="12" label="Pathophysiology"/><FilterOption id="17" count="10" label="Biomarker identification"/><FilterOption id="19" count="2" label="Surgical procedure"/><FilterOption id="10" count="1" label="Borderline product"/><FilterOption id="13" count="1" label="Hospital solutions"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="1085" label="Yes"/><FilterOption id="NO" count="931" label="No"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="67136" count="74" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="3808" count="69" label="Kit tyrosine kinase inhibitor"/><FilterOption id="14007" count="64" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="740" count="62" label="Epidermal growth factor receptor antagonist"/><FilterOption id="3848" count="57" label="VEGF-2 receptor antagonist"/><FilterOption id="1832" count="55" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="5085" count="53" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="3846" count="53" label="VEGF-1 receptor antagonist"/><FilterOption id="3850" count="52" label="VEGF-3 receptor antagonist"/><FilterOption id="1016" count="51" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="3756" count="44" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="3806" count="44" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="4548" count="42" label="Raf B protein kinase inhibitor"/><FilterOption id="4917" count="41" label="Proteasome inhibitor"/><FilterOption id="204" count="40" label="HIV protease inhibitor"/><FilterOption id="7588" count="40" label="HIV-1 integrase inhibitor"/><FilterOption id="948" count="40" label="PDGF receptor antagonist"/><FilterOption id="138" count="39" label="DNA polymerase inhibitor"/><FilterOption id="10240" count="38" label="mTOR inhibitor"/><FilterOption id="5482" count="36" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="48492" count="36" label="PDGF receptor beta antagonist"/><FilterOption id="372" count="36" label="Thymidylate synthase inhibitor"/><FilterOption id="120" count="33" label="Factor Xa antagonist"/><FilterOption id="768" count="33" label="HIV-1 protease inhibitor"/><FilterOption id="12521" count="33" label="VEGF ligand inhibitor"/><FilterOption id="3816" count="32" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="3562" count="30" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="76" count="29" label="Aromatase inhibitor"/><FilterOption id="3754" count="29" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="1722" count="29" label="VEGF receptor antagonist"/><FilterOption id="76469" count="28" label="26S proteasome complex inhibitor"/><FilterOption id="4010" count="28" label="Calcineurin inhibitor"/><FilterOption id="4762" count="27" label="MEK-1 protein kinase inhibitor"/><FilterOption id="4764" count="27" label="MEK-2 protein kinase inhibitor"/><FilterOption id="142" count="27" label="Topoisomerase II inhibitor"/><FilterOption id="48489" count="25" label="PDGF receptor alpha antagonist"/><FilterOption id="7424" count="24" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="3688" count="24" label="FGF3 receptor antagonist"/><FilterOption id="76090" count="24" label="mTOR complex 1 inhibitor"/><FilterOption id="13571" count="23" label="Bcr protein inhibitor"/><FilterOption id="770" count="23" label="Endothelin ET-A receptor antagonist"/><FilterOption id="675" count="23" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="1833" count="23" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="3682" count="22" label="FGF1 receptor antagonist"/><FilterOption id="38283" count="22" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="22" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="3524" count="21" label="Abl tyrosine kinase inhibitor"/><FilterOption id="286" count="21" label="Estrogen receptor antagonist"/><FilterOption id="629" count="20" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="135" count="19" label="DHFR inhibitor"/><FilterOption id="385" count="19" label="Protein tyrosine kinase inhibitor"/><FilterOption id="721" count="19" label="TNF binding agent"/><FilterOption id="4314" count="18" label="Cyclin-dependent kinase-4 inhibitor"/><FilterOption id="4318" count="18" label="Cyclin-dependent kinase-6 inhibitor"/><FilterOption id="2585" count="18" label="Glucagon-like peptide 1 receptor agonist"/><FilterOption id="214" count="18" label="Interferon alpha 2 ligand"/><FilterOption id="3592" count="17" label="Btk tyrosine kinase inhibitor"/><FilterOption id="181" count="17" label="GAR transformylase inhibitor"/><FilterOption id="205" count="17" label="HMG CoA reductase inhibitor"/><FilterOption id="4760" count="17" label="MEK protein kinase inhibitor"/><FilterOption id="1575" count="17" label="Phosphoinositide 3-kinase inhibitor"/><FilterOption id="4550" count="17" label="Raf 1 protein kinase inhibitor"/><FilterOption id="3576" count="17" label="Src tyrosine kinase inhibitor"/><FilterOption id="374" count="17" label="Transferase inhibitor"/><FilterOption id="3154" count="16" label="CSF-1 antagonist"/><FilterOption id="3685" count="16" label="FGF2 receptor antagonist"/><FilterOption id="3818" count="16" label="Ret tyrosine kinase receptor inhibitor"/><FilterOption id="551" count="16" label="RNA DNA polymerase inhibitor"/><FilterOption id="431" count="15" label="DNA gyrase inhibitor"/><FilterOption id="381" count="15" label="TNF alpha ligand inhibitor"/><FilterOption id="5136" count="14" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="60" count="14" label="Androgen receptor antagonist"/><FilterOption id="168" count="14" label="FGF receptor antagonist"/><FilterOption id="12395" count="14" label="HIV GAG protein inhibitor"/><FilterOption id="471" count="14" label="IL-6 receptor antagonist"/><FilterOption id="3560" count="14" label="JAK tyrosine kinase inhibitor"/><FilterOption id="3564" count="14" label="Jak2 tyrosine kinase inhibitor"/><FilterOption id="3584" count="14" label="Lck tyrosine kinase inhibitor"/><FilterOption id="2507" count="14" label="PARP inhibitor"/><FilterOption id="778" count="14" label="PDE 5 inhibitor"/><FilterOption id="3834" count="14" label="Tek tyrosine kinase receptor inhibitor"/><FilterOption id="3107" count="13" label="CCR5 chemokine antagonist"/><FilterOption id="144" count="13" label="Dopamine receptor agonist"/><FilterOption id="771" count="13" label="Endothelin ET-B receptor antagonist"/><FilterOption id="1671" count="13" label="HIV integrase inhibitor"/><FilterOption id="3566" count="13" label="Jak3 tyrosine kinase inhibitor"/><FilterOption id="3796" count="13" label="MET tyrosine kinase receptor family inhibitor"/><FilterOption id="2506" count="13" label="PARP modulator"/><FilterOption id="38289" count="13" label="Poly ADP ribose polymerase 3 inhibitor"/><FilterOption id="11778" count="13" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="347" count="13" label="RNA polymerase inhibitor"/><FilterOption id="141" count="13" label="Topoisomerase I inhibitor"/><FilterOption id="585" count="12" label="5-HT 2a receptor antagonist"/><FilterOption id="621" count="12" label="Amyloid protein deposition inhibitor"/><FilterOption id="71851" count="12" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="4802" count="12" label="IL-17 antagonist"/><FilterOption id="226" count="12" label="IL-5 receptor antagonist"/><FilterOption id="1689" count="12" label="VEGF-A ligand inhibitor"/><FilterOption id="5027" count="11" label="CD4 agonist"/><FilterOption id="7472" count="11" label="Cytochrome P450 17 inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="28355" count="28" label="GlaxoSmithKline plc"/><FilterOption id="1017818" count="21" label="Instituto de Salud Carlos III"/><FilterOption id="18767" count="21" label="Pfizer Inc"/><FilterOption id="19446" count="19" label="Roche Holding AG"/><FilterOption id="1039423" count="18" label="Hospital Clinic of Barcelona"/><FilterOption id="15331" count="17" label="Celgene Corp"/><FilterOption id="19453" count="16" label="Genentech Inc"/><FilterOption id="20300" count="16" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="1013295" count="15" label="Astellas Pharma Inc"/><FilterOption id="1067538" count="15" label="Janssen Research &amp; Development LLC"/><FilterOption id="1059823" count="15" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="15065" count="14" label="Bristol-Myers Squibb Co"/><FilterOption id="23137" count="14" label="Novartis AG"/><FilterOption id="19214" count="13" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="14190" count="12" label="AstraZeneca plc"/><FilterOption id="14109" count="11" label="Amgen Inc"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="17810" count="9" label="Eli Lilly &amp; Co"/><FilterOption id="1039086" count="9" label="Germans Trias i Pujol Hospital"/><FilterOption id="1017771" count="9" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="18681" count="9" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="13601" count="7" label="Abbott Laboratories"/><FilterOption id="1072507" count="7" label="AbbVie Inc"/><FilterOption id="1059977" count="7" label="European Commission"/><FilterOption id="26178" count="7" label="F Hoffmann-La Roche AG"/><FilterOption id="1101929" count="7" label="IQVIA Holdings Inc"/><FilterOption id="17416" count="7" label="Janssen LP"/><FilterOption id="18077" count="7" label="Merck &amp; Co Inc"/><FilterOption id="1053612" count="6" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="1061163" count="5" label="Abbott Vascular"/><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="25902" count="5" label="Array BioPharma Inc"/><FilterOption id="14455" count="5" label="Bayer AG"/><FilterOption id="19620" count="5" label="Eisai Inc"/><FilterOption id="1104124" count="5" label="GlaxoSmithKline LLC"/><FilterOption id="1045910" count="5" label="Hospital Clinico San Carlos"/><FilterOption id="17401" count="5" label="Janssen-Cilag SA"/><FilterOption id="17332" count="5" label="Johnson &amp; Johnson"/><FilterOption id="29481" count="5" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"/><FilterOption id="20519" count="5" label="National Cancer Institute"/><FilterOption id="1033116" count="5" label="PAREXEL International"/><FilterOption id="1067340" count="5" label="Pivotal SL"/><FilterOption id="1009547" count="5" label="Sanofi SA"/><FilterOption id="25554" count="5" label="Seattle Genetics Inc"/><FilterOption id="21082" count="5" label="Walter and Eliza Hall Institute of Medical Research"/><FilterOption id="1041980" count="4" label="Charite University"/><FilterOption id="15414" count="4" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"/><FilterOption id="22676" count="4" label="Exelixis Inc"/><FilterOption id="1073758" count="4" label="Fondo de Investigacion Sanitaria"/><FilterOption id="1044293" count="4" label="German CLL Study Group"/><FilterOption id="28959" count="4" label="Hannover Medical School"/><FilterOption id="1040862" count="4" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1003065" count="4" label="Hospital Vall D'Hebron"/><FilterOption id="18438" count="4" label="Medical Research Council"/><FilterOption id="18101" count="4" label="Merck KGaA"/><FilterOption id="1074428" count="4" label="Ministerio de Economia y Competitividad"/><FilterOption id="1055006" count="4" label="Ministry of Health, Spain"/><FilterOption id="1053488" count="4" label="NCIC Clinical Trials Group"/><FilterOption id="1116693" count="4" label="Productos Roche, S.A. de C.V."/><FilterOption id="19898" count="4" label="Shionogi &amp; Co Ltd"/><FilterOption id="21279" count="4" label="Universite Catholique de Louvain"/><FilterOption id="1038808" count="3" label="Azienda Ospedaliera di Padova"/><FilterOption id="1052569" count="3" label="B Braun Surgical Sa"/><FilterOption id="1005244" count="3" label="Biogen Inc"/><FilterOption id="14881" count="3" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1103224" count="3" label="Centro Hospitalar do Porto"/><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"/><FilterOption id="1018807" count="3" label="Covance Inc"/><FilterOption id="1020322" count="3" label="Daiichi Sankyo Inc"/><FilterOption id="1062976" count="3" label="Europath Biosciences Sl"/><FilterOption id="1063203" count="3" label="Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico"/><FilterOption id="1039087" count="3" label="Fundacio Lluita Contra La Sida"/><FilterOption id="1033112" count="3" label="Hospital Universitario 12 de Octubre"/><FilterOption id="1006639" count="3" label="Hospital Universitario Ramon y Cajal"/><FilterOption id="1068275" count="3" label="Innovative Medicines Initiative"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1056690" count="3" label="Institut Investigació Biomèdica Bellvitge"/><FilterOption id="17392" count="3" label="Janssen-Cilag Ltd"/><FilterOption id="21110" count="3" label="Karolinska Institutet"/><FilterOption id="1075878" count="3" label="Klinikum der Universität Köln"/><FilterOption id="22137" count="3" label="Ludwig-Maximilians University of Munich"/><FilterOption id="1014884" count="3" label="Medivation Inc"/><FilterOption id="1175391" count="3" label="Medivation LLC"/><FilterOption id="21404" count="3" label="MorphoSys AG"/><FilterOption id="20520" count="3" label="National Institute of Allergy and Infectious Diseases"/><FilterOption id="18683" count="3" label="Onyx Pharmaceuticals Inc"/><FilterOption id="19087" count="3" label="Pierre Fabre SA"/><FilterOption id="1114888" count="3" label="Quartz Bio SA"/><FilterOption id="1119200" count="3" label="Sanofi-Aventis Research and Development"/><FilterOption id="1058089" count="3" label="Servicio Andaluz De Salud"/><FilterOption id="1096345" count="3" label="Servicio Cántabro De Salud"/><FilterOption id="21991" count="3" label="Takeda Oncology"/><FilterOption id="1054559" count="3" label="TESARO Inc"/><FilterOption id="1114403" count="3" label="TFS Trial Form Support"/><FilterOption id="1119462" count="3" label="The Cyprus Foundation For Muscular Dystrophy Research"/><FilterOption id="1104050" count="3" label="UCB Biopharma SPRL"/><FilterOption id="20625" count="3" label="Universita degli Studi di Milano"/><FilterOption id="1003992" count="3" label="Universitat de Barcelona"/><FilterOption id="1042041" count="3" label="University Hospital, Brest"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="100"><FilterOption id="1545" count="257" label="Anticancer"/><FilterOption id="767" count="88" label="Cell cycle inhibitor"/><FilterOption id="2953" count="81" label="Anti-inflammatory"/><FilterOption id="991" count="76" label="Antiviral"/><FilterOption id="55685" count="68" label="Anticancer monoclonal antibody"/><FilterOption id="1569" count="61" label="Anticancer antimetabolite"/><FilterOption id="62255" count="61" label="Anticancer protein kinase inhibitor"/><FilterOption id="140" count="58" label="DNA synthesis inhibitor"/><FilterOption id="50" count="54" label="Anticancer alkylating agent"/><FilterOption id="1589" count="53" label="Apoptosis stimulator"/><FilterOption id="2575" count="41" label="Microtubule inhibitor"/><FilterOption id="61" count="36" label="Angiogenesis inhibitor"/><FilterOption id="2576" count="34" label="Microtubule stabilizer"/><FilterOption id="2660" count="32" label="Vasoprotectant"/><FilterOption id="7293" count="27" label="Synergist"/><FilterOption id="396" count="25" label="Immunosuppressant"/><FilterOption id="659" count="21" label="Coagulation inhibitor"/><FilterOption id="747" count="18" label="HIV replication inhibitor"/><FilterOption id="1594" count="17" label="Antibacterial"/><FilterOption id="399" count="17" label="Hypoglycemic agent"/><FilterOption id="1596" count="17" label="Immunomodulator"/><FilterOption id="393" count="16" label="Immunostimulant"/><FilterOption id="7761" count="16" label="T-lymphocyte stimulator"/><FilterOption id="750" count="15" label="DNA intercalator"/><FilterOption id="2657" count="13" label="Antihypertensive"/><FilterOption id="7760" count="12" label="T-lymphocyte inhibitor"/><FilterOption id="2946" count="11" label="Analgesic"/><FilterOption id="610" count="11" label="Hematopoietic stimulator"/><FilterOption id="104" count="10" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="15187" count="10" label="Systemic dermatological antibacterial product"/><FilterOption id="62254" count="9" label="Anticancer hormone antagonist"/><FilterOption id="15184" count="9" label="Systemic antipsoriatic product"/><FilterOption id="38206" count="8" label="Biguanide antidiabetic product"/><FilterOption id="664" count="8" label="Fibrosuppressant"/><FilterOption id="805" count="8" label="Folate modulator"/><FilterOption id="312" count="8" label="Platelet aggregation inhibitor"/><FilterOption id="382" count="8" label="TNF alpha synthesis inhibitor"/><FilterOption id="937" count="7" label="Androgen synthesis inhibitor"/><FilterOption id="2659" count="7" label="Cardioprotectant"/><FilterOption id="1748" count="7" label="Fungicide"/><FilterOption id="3189" count="6" label="Corticosteroid agonist"/><FilterOption id="32411" count="6" label="Hepatitis B virus replication inhibitor"/><FilterOption id="38215" count="6" label="Human insulin long acting product"/><FilterOption id="439" count="6" label="RNA synthesis inhibitor"/><FilterOption id="1479" count="6" label="RNA synthesis modulator"/><FilterOption id="2954" count="6" label="Steroidal anti-inflammatory"/><FilterOption id="388" count="6" label="Vasodilator"/><FilterOption id="70" count="5" label="Anticonvulsant agent"/><FilterOption id="71" count="5" label="Antihypercholesterolemic agent"/><FilterOption id="1538" count="5" label="Bacterial protein synthesis inhibitor"/><FilterOption id="646" count="5" label="Bronchodilator"/><FilterOption id="38211" count="5" label="Human insulin fast acting product"/><FilterOption id="1532" count="5" label="Viral replication inhibitor"/><FilterOption id="2947" count="4" label="Antiparkinsonian"/><FilterOption id="3984" count="4" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="3246" count="4" label="Insulin release stimulator"/><FilterOption id="1615" count="4" label="Neuroprotectant"/><FilterOption id="1129" count="4" label="Non-steroid hormone receptor antagonist"/><FilterOption id="15148" count="4" label="Ocular antineovascularisation agent"/><FilterOption id="12378" count="4" label="Prophylactic vaccine"/><FilterOption id="463" count="4" label="Ribosome binding agent"/><FilterOption id="38205" count="4" label="Sulphonylurea antidiabetic product"/><FilterOption id="15178" count="4" label="Systemic dermatological antifungal product"/><FilterOption id="882" count="3" label="5-HETE modulator"/><FilterOption id="2941" count="3" label="Antidepressant"/><FilterOption id="89" count="3" label="Bone resorption inhibitor"/><FilterOption id="1537" count="3" label="Cephalosporin"/><FilterOption id="695" count="3" label="Metastasis inhibitor"/><FilterOption id="563" count="3" label="Microtubule modulator"/><FilterOption id="12596" count="3" label="Osteoclast inhibitor"/><FilterOption id="449" count="2" label="Antiarrhythmic agent"/><FilterOption id="2638" count="2" label="Antiparasitic"/><FilterOption id="5704" count="2" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="2" label="B-lymphocyte migration inhibitor"/><FilterOption id="5580" count="2" label="Chemotaxis inhibitor"/><FilterOption id="7211" count="2" label="CNS diagnostic agent"/><FilterOption id="11593" count="2" label="DNA repair inhibitor"/><FilterOption id="38439" count="2" label="DPP IV inhibitor antidiabetic product"/><FilterOption id="161" count="2" label="Ergosterol synthesis inhibitor"/><FilterOption id="3313" count="2" label="Glucagon-like peptide 1 metabolism modulator"/><FilterOption id="12367" count="2" label="Inactivated viral vaccine"/><FilterOption id="1540" count="2" label="Macrolide antibiotic"/><FilterOption id="284" count="2" label="Nootropic agent"/><FilterOption id="15128" count="2" label="Ophthalmological agent"/><FilterOption id="5555" count="2" label="PET contrast agent"/><FilterOption id="5542" count="2" label="Pyrimidine nucleotide metabolism modulator"/><FilterOption id="5720" count="2" label="Radiodiagnostic"/><FilterOption id="26035" count="2" label="siRNA agent"/><FilterOption id="15180" count="2" label="Topical antipruritic product"/><FilterOption id="38200" count="1" label="Acid pump inhibitor antiulcerant product"/><FilterOption id="2970" count="1" label="Anti-emetic"/><FilterOption id="2667" count="1" label="Antiarteriosclerotic"/><FilterOption id="62253" count="1" label="Anticancer hormone"/><FilterOption id="15135" count="1" label="Antiglaucoma agent"/><FilterOption id="72" count="1" label="Antihyperlipidemic agent"/><FilterOption id="7018" count="1" label="Antihypertriglyceridemic agent"/><FilterOption id="955" count="1" label="Antimicrobial permeability enhancer"/><FilterOption id="2943" count="1" label="Antipsychotic"/><FilterOption id="2942" count="1" label="Anxiolytic"/><FilterOption id="1535" count="1" label="Beta lactam antibiotic"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="1068" label="Proteomic"/><FilterOption id="38" count="1043" label="Genomic"/><FilterOption id="31" count="510" label="Physiological"/><FilterOption id="32" count="508" label="Biochemical"/><FilterOption id="75" count="397" label="Cellular"/><FilterOption id="39" count="187" label="Anthropomorphic"/><FilterOption id="40" count="183" label="Structural (imaging)"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="1119" label="Therapeutic effect marker"/><FilterOption id="1571666123" count="494" label="Disease marker"/><FilterOption id="730490367" count="382" label="Toxic effect marker"/><FilterOption id="3242045531" count="6" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="3803" count="46" label="paclitaxel"/><FilterOption id="44383" count="43" label="carboplatin"/><FilterOption id="3199" count="36" label="gemcitabine"/><FilterOption id="6736" count="36" label="rituximab"/><FilterOption id="72699" count="34" label="atezolizumab"/><FilterOption id="8047" count="33" label="bevacizumab"/><FilterOption id="54804" count="32" label="nivolumab"/><FilterOption id="27572" count="31" label="lenalidomide"/><FilterOption id="2953" count="29" label="docetaxel"/><FilterOption id="15954" count="28" label="bortezomib"/><FilterOption id="6386" count="26" label="trastuzumab"/><FilterOption id="36630" count="23" label="ipilimumab"/><FilterOption id="70667" count="23" label="pembrolizumab"/><FilterOption id="7310" count="23" label="ritonavir"/><FilterOption id="14681" count="21" label="lopinavir + ritonavir"/><FilterOption id="13340" count="20" label="everolimus"/><FilterOption id="3792" count="20" label="oxaliplatin"/><FilterOption id="54488" count="20" label="raltegravir"/><FilterOption id="12205" count="19" label="capecitabine"/><FilterOption id="11961" count="19" label="erlotinib"/><FilterOption id="81193" count="17" label="durvalumab"/><FilterOption id="2784" count="17" label="letrozole"/><FilterOption id="3536" count="17" label="pemetrexed disodium"/><FilterOption id="5369" count="16" label="ribavirin"/><FilterOption id="32677" count="16" label="rivaroxaban"/><FilterOption id="3072" count="14" label="etoposide phosphate"/><FilterOption id="3474" count="14" label="lamivudine"/><FilterOption id="14163" count="13" label="adalimumab"/><FilterOption id="47000" count="13" label="bendamustine"/><FilterOption id="3313" count="13" label="fulvestrant"/><FilterOption id="55237" count="13" label="ibrutinib"/><FilterOption id="3669" count="13" label="mycophenolate mofetil"/><FilterOption id="4510" count="13" label="tacrolimus"/><FilterOption id="15254" count="12" label="atazanavir"/><FilterOption id="59062" count="12" label="dolutegravir"/><FilterOption id="3081" count="12" label="exemestane"/><FilterOption id="16063" count="12" label="olaparib"/><FilterOption id="23625" count="12" label="peginterferon alfa-2a"/><FilterOption id="29831" count="12" label="sorafenib"/><FilterOption id="49219" count="12" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="14493" count="12" label="tenofovir disoproxil fumarate"/><FilterOption id="45499" count="12" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="10309" count="11" label="abiraterone"/><FilterOption id="54601" count="11" label="carfilzomib"/><FilterOption id="6156" count="11" label="fludarabine"/><FilterOption id="37613" count="11" label="maraviroc"/><FilterOption id="29016" count="11" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="83065" count="10" label="avelumab"/><FilterOption id="37370" count="10" label="azacitidine"/><FilterOption id="5999" count="10" label="ciclosporin, Novartis"/><FilterOption id="32981" count="10" label="darunavir"/><FilterOption id="10172" count="10" label="efavirenz"/><FilterOption id="4728" count="10" label="emtricitabine"/><FilterOption id="28532" count="10" label="pertuzumab"/><FilterOption id="55275" count="10" label="secukinumab"/><FilterOption id="4200" count="10" label="sirolimus"/><FilterOption id="55288" count="10" label="trametinib"/><FilterOption id="45562" count="10" label="tremelimumab"/><FilterOption id="54469" count="10" label="vemurafenib"/><FilterOption id="56544" count="9" label="cobimetinib"/><FilterOption id="53133" count="9" label="dabrafenib"/><FilterOption id="2871" count="9" label="irinotecan"/><FilterOption id="6050" count="9" label="metformin hydrochloride"/><FilterOption id="11519" count="9" label="mitoxantrone"/><FilterOption id="53227" count="9" label="obinutuzumab"/><FilterOption id="4529" count="9" label="temozolomide"/><FilterOption id="6259" count="9" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="55305" count="8" label="binimetinib"/><FilterOption id="61901" count="8" label="buparlisib"/><FilterOption id="10388" count="8" label="cetuximab"/><FilterOption id="2836" count="8" label="clopidogrel"/><FilterOption id="53200" count="8" label="daratumumab"/><FilterOption id="48181" count="8" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="12037" count="8" label="mepolizumab"/><FilterOption id="35644" count="8" label="methoxy polyethylene glycol-epoetin beta"/><FilterOption id="27696" count="8" label="pomalidomide"/><FilterOption id="17814" count="8" label="pregabalin"/><FilterOption id="54614" count="8" label="riociguat"/><FilterOption id="96193" count="8" label="spartalizumab"/><FilterOption id="6242" count="7" label="abacavir"/><FilterOption id="39518" count="7" label="albiglutide"/><FilterOption id="2807" count="7" label="atorvastatin"/><FilterOption id="53981" count="7" label="enzalutamide"/><FilterOption id="57369" count="7" label="etrolizumab"/><FilterOption id="65240" count="7" label="evolocumab"/><FilterOption id="45841" count="7" label="lenvatinib mesylate"/><FilterOption id="52854" count="7" label="macitentan"/><FilterOption id="50040" count="7" label="tacrolimus (oral sustained-release), Astellas"/><FilterOption id="74726" count="7" label="upadacitinib"/><FilterOption id="3321" count="6" label="anastrozole"/><FilterOption id="7781" count="6" label="aripiprazole"/><FilterOption id="4567" count="6" label="etanercept"/><FilterOption id="65360" count="6" label="ribociclib"/><FilterOption id="8713" count="6" label="sildenafil citrate"/><FilterOption id="70895" count="6" label="venetoclax"/><FilterOption id="53547" count="5" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="52967" count="5" label="apixaban"/><FilterOption id="5871" count="5" label="bosentan"/><FilterOption id="30379" count="5" label="bosutinib"/><FilterOption id="50935" count="5" label="cabozantinib S-malate"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="9213" count="44" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="8713" count="38" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8489" count="31" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9247" count="29" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7908" count="25" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9153" count="22" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7547" count="22" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="3736" count="20" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"/><FilterOption id="7367" count="20" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="2622" count="19" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="8481" count="19" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7360" count="19" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8721" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="6924" count="18" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10830" count="18" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6863" count="17" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="9212" count="17" label="HIV infection - Assessment of Viral Load"/><FilterOption id="8140" count="17" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="7563" count="17" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="1359" count="17" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"/><FilterOption id="8719" count="16" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="9218" count="16" label="HIV infection - Assessment of Immune Response"/><FilterOption id="8078" count="16" label="Leukemia - Assessment of adverse events"/><FilterOption id="25660" count="16" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="8744" count="15" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="2492" count="15" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="9215" count="15" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="7909" count="15" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="9155" count="15" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="6972" count="15" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="10545" count="15" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15907" count="15" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="8505" count="14" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7049" count="14" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15293" count="14" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="15287" count="14" label="Solid tumor - Assessment of adverse events"/><FilterOption id="17220" count="13" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="9238" count="13" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8523" count="13" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8714" count="12" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8998" count="12" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8163" count="12" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="22545" count="12" label="End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels"/><FilterOption id="9197" count="12" label="HIV infection - Assessment of virological response - Assessment of virological failure"/><FilterOption id="7569" count="12" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7372" count="12" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="15285" count="12" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="11773" count="11" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8720" count="11" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="12048" count="11" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7891" count="11" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7916" count="11" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="6919" count="11" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="6940" count="11" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="42921" count="11" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="10895" count="11" label="Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8759" count="10" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="3809" count="10" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9272" count="10" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="23916" count="10" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="2" count="10" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"/><FilterOption id="7879" count="10" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="7919" count="10" label="Leukemia - Assessment of Response Rates (RR) - Assessment of molecular response"/><FilterOption id="8090" count="10" label="Leukemia - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="23051" count="10" label="Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)"/><FilterOption id="7373" count="10" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="14204" count="10" label="Myeloproliferative disorder - Assessment of Response Rates (RR)"/><FilterOption id="10247" count="10" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of pulmonary embolism(PE)"/><FilterOption id="2286" count="9" label="Alzheimers disease - Assessment of Adverse Events"/><FilterOption id="2410" count="9" label="Alzheimers disease - Assessment of Safety and Tolerability"/><FilterOption id="17356" count="9" label="Anemia - Assessment of adverse events"/><FilterOption id="9504" count="9" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"/><FilterOption id="9510" count="9" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="11949" count="9" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="8996" count="9" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="8436" count="9" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="22506" count="9" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"/><FilterOption id="9255" count="9" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="9195" count="9" label="HIV infection - Assessment of virological response"/><FilterOption id="18111" count="9" label="Insulin dependent diabetes - Assessment of HbA1c Levels"/><FilterOption id="7935" count="9" label="Leukemia - Assessment of Disease Progression"/><FilterOption id="7914" count="9" label="Leukemia - Assessment of Response Rates (RR) - Assessment of cytogenetic response"/><FilterOption id="8077" count="9" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="8640" count="9" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7680" count="9" label="Lymphoma - Assessment of adverse events"/><FilterOption id="6952" count="9" label="Melanoma - Assessment of Disease Progression"/><FilterOption id="15212" count="9" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="12148" count="9" label="Stomach tumor - Assessment of Overall Survival (OS)"/><FilterOption id="10243" count="9" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of venous thrombosis/thromboembolism"/><FilterOption id="2332" count="8" label="Alzheimers disease - Assessment of Dementia - Clinical dementia rating sum of boxes (CDR-SOB)"/><FilterOption id="37159" count="8" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="9008" count="8" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="6339" count="8" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="22587" count="8" label="End stage renal disease - Assessment of Disease Progression"/><FilterOption id="7244" count="8" label="Head and neck tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9242" count="8" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="8109" count="8" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="7907" count="8" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8555" count="8" label="Lung tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8514" count="8" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="19446" count="162" label="Roche Holding AG"/><FilterOption id="23137" count="138" label="Novartis AG"/><FilterOption id="18767" count="134" label="Pfizer Inc"/><FilterOption id="1039423" count="131" label="Hospital Clinic of Barcelona"/><FilterOption id="28355" count="116" label="GlaxoSmithKline plc"/><FilterOption id="14455" count="88" label="Bayer AG"/><FilterOption id="26178" count="84" label="F Hoffmann-La Roche AG"/><FilterOption id="15065" count="77" label="Bristol-Myers Squibb Co"/><FilterOption id="15331" count="48" label="Celgene Corp"/><FilterOption id="14190" count="46" label="AstraZeneca plc"/><FilterOption id="14109" count="45" label="Amgen Inc"/><FilterOption id="17810" count="45" label="Eli Lilly &amp; Co"/><FilterOption id="1009547" count="43" label="Sanofi SA"/><FilterOption id="1038736" count="42" label="PETHEMA Foundation"/><FilterOption id="16450" count="41" label="Gilead Sciences Inc"/><FilterOption id="25599" count="39" label="Novartis Pharma AG"/><FilterOption id="1144568" count="39" label="Novartis Pharma Services AG"/><FilterOption id="19453" count="38" label="Genentech Inc"/><FilterOption id="1072507" count="37" label="AbbVie Inc"/><FilterOption id="1003983" count="37" label="Bayer HealthCare AG"/><FilterOption id="1059823" count="34" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="14881" count="33" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1067538" count="33" label="Janssen Research &amp; Development LLC"/><FilterOption id="1013295" count="31" label="Astellas Pharma Inc"/><FilterOption id="15133" count="25" label="Bristol-Myers Squibb International Corp"/><FilterOption id="15414" count="25" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1050515" count="24" label="ViiV Healthcare Ltd"/><FilterOption id="30062" count="23" label="AstraZeneca AB"/><FilterOption id="1017818" count="23" label="Instituto de Salud Carlos III"/><FilterOption id="13601" count="22" label="Abbott Laboratories"/><FilterOption id="29218" count="22" label="AbbVie Deutschland GmbH &amp; Co KG"/><FilterOption id="1053612" count="21" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="1119200" count="21" label="Sanofi-Aventis Research and Development"/><FilterOption id="20300" count="20" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="23780" count="18" label="Actelion Ltd"/><FilterOption id="1121088" count="18" label="Novartis Farmaceutica SA"/><FilterOption id="1145220" count="17" label="GlaxoSmithKline Research &amp; Development Ltd"/><FilterOption id="27847" count="16" label="Boston Scientific Corp"/><FilterOption id="1039086" count="16" label="Germans Trias i Pujol Hospital"/><FilterOption id="1042061" count="16" label="Spanish Breast Cancer Research Group"/><FilterOption id="1091809" count="15" label="Janssen-Cilag International NV (BE)"/><FilterOption id="22546" count="14" label="Boehringer Ingelheim GmbH"/><FilterOption id="1017513" count="14" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="1017771" count="14" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="19214" count="14" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="15121" count="13" label="Bristol-Myers Squibb Belgium SA"/><FilterOption id="1110770" count="13" label="Novartis Farma SpA"/><FilterOption id="1042371" count="13" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="28611" count="12" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="25902" count="12" label="Array BioPharma Inc"/><FilterOption id="1005244" count="12" label="Biogen Inc"/><FilterOption id="27053" count="12" label="Glaxo Group Research Ltd"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1003065" count="12" label="Hospital Vall D'Hebron"/><FilterOption id="1095980" count="12" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."/><FilterOption id="21991" count="12" label="Takeda Oncology"/><FilterOption id="1020322" count="11" label="Daiichi Sankyo Inc"/><FilterOption id="19620" count="11" label="Eisai Inc"/><FilterOption id="1087775" count="11" label="Novartis Oncology"/><FilterOption id="18681" count="11" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="1051470" count="10" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="18077" count="10" label="Merck &amp; Co Inc"/><FilterOption id="18614" count="10" label="Novo Nordisk A/S"/><FilterOption id="1143375" count="9" label="AbbVie Pte Ltd"/><FilterOption id="22554" count="9" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="9" label="Boehringer Ingelheim Corp"/><FilterOption id="17839" count="9" label="Eli Lilly SA"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1052299" count="9" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="17332" count="9" label="Johnson &amp; Johnson"/><FilterOption id="18008" count="9" label="MedImmune LLC"/><FilterOption id="1097361" count="9" label="Medtronic plc"/><FilterOption id="13979" count="8" label="Alexion Pharmaceuticals Inc"/><FilterOption id="1104124" count="8" label="GlaxoSmithKline LLC"/><FilterOption id="19461" count="8" label="Hoffmann-La Roche Inc"/><FilterOption id="17216" count="8" label="Incyte Corp"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="18101" count="8" label="Merck KGaA"/><FilterOption id="1058600" count="8" label="Novartis India"/><FilterOption id="25554" count="8" label="Seattle Genetics Inc"/><FilterOption id="20972" count="7" label="Astellas Pharma Europe Ltd"/><FilterOption id="1059977" count="7" label="European Commission"/><FilterOption id="27108" count="7" label="Glaxo SA"/><FilterOption id="24166" count="7" label="GlaxoSmithKline Biologicals"/><FilterOption id="1040940" count="7" label="Hospital Universitari de Bellvitge"/><FilterOption id="1101929" count="7" label="IQVIA Holdings Inc"/><FilterOption id="17416" count="7" label="Janssen LP"/><FilterOption id="18683" count="7" label="Onyx Pharmaceuticals Inc"/><FilterOption id="19063" count="7" label="Pharmacyclics Inc"/><FilterOption id="14112" count="7" label="Wyeth"/><FilterOption id="1037956" count="6" label="Astellas Pharma Global Development Inc"/><FilterOption id="1103352" count="6" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="22563" count="6" label="Boehringer Ingelheim Ltd"/><FilterOption id="22676" count="6" label="Exelixis Inc"/><FilterOption id="1042252" count="6" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1045910" count="6" label="Hospital Clinico San Carlos"/><FilterOption id="1072647" count="6" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="15938" count="6" label="Millennium Pharmaceuticals Ltd"/><FilterOption id="20520" count="6" label="National Institute of Allergy and Infectious Diseases"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="65" label="2019-01-24"/><FilterOption count="40" label="2019-01-25"/><FilterOption count="39" label="2019-01-26"/><FilterOption count="33" label="2019-07-02"/><FilterOption count="32" label="2018-10-14"/><FilterOption count="30" label="2019-06-21"/><FilterOption count="29" label="2019-07-03"/><FilterOption count="28" label="2019-06-14"/><FilterOption count="28" label="2019-06-20"/><FilterOption count="27" label="2018-10-12"/><FilterOption count="27" label="2019-06-19"/><FilterOption count="27" label="2019-06-25"/><FilterOption count="27" label="2019-06-27"/><FilterOption count="26" label="2019-06-07"/><FilterOption count="26" label="2019-06-28"/><FilterOption count="25" label="2018-10-15"/><FilterOption count="25" label="2019-03-07"/><FilterOption count="25" label="2019-06-26"/><FilterOption count="25" label="2019-07-01"/><FilterOption count="23" label="2018-10-13"/><FilterOption count="23" label="2019-06-06"/><FilterOption count="22" label="2019-06-12"/><FilterOption count="21" label="2019-06-17"/><FilterOption count="19" label="2019-06-13"/><FilterOption count="16" label="2013-12-02"/><FilterOption count="15" label="2019-05-23"/><FilterOption count="14" label="2019-05-17"/><FilterOption count="14" label="2019-05-22"/><FilterOption count="14" label="2019-05-31"/><FilterOption count="14" label="2019-06-10"/><FilterOption count="14" label="2019-06-18"/><FilterOption count="13" label="2018-07-07"/><FilterOption count="13" label="2019-02-07"/><FilterOption count="12" label="2019-05-24"/><FilterOption count="12" label="2019-05-27"/><FilterOption count="11" label="2018-12-05"/><FilterOption count="11" label="2019-06-11"/><FilterOption count="11" label="2019-06-22"/><FilterOption count="10" label="2018-10-16"/><FilterOption count="10" label="2019-04-22"/><FilterOption count="10" label="2019-05-07"/><FilterOption count="10" label="2019-05-10"/><FilterOption count="10" label="2019-06-04"/><FilterOption count="10" label="2019-06-24"/><FilterOption count="9" label="2018-06-09"/><FilterOption count="9" label="2018-07-14"/><FilterOption count="9" label="2018-12-12"/><FilterOption count="9" label="2018-12-14"/><FilterOption count="9" label="2019-04-05"/><FilterOption count="8" label="2018-06-23"/><FilterOption count="8" label="2018-11-20"/><FilterOption count="8" label="2018-12-18"/><FilterOption count="8" label="2019-02-04"/><FilterOption count="8" label="2019-04-15"/><FilterOption count="8" label="2019-06-05"/><FilterOption count="7" label="2013-09-14"/><FilterOption count="7" label="2018-01-24"/><FilterOption count="7" label="2018-03-01"/><FilterOption count="7" label="2018-05-26"/><FilterOption count="7" label="2018-11-12"/><FilterOption count="7" label="2018-12-11"/><FilterOption count="7" label="2018-12-13"/><FilterOption count="7" label="2019-02-08"/><FilterOption count="7" label="2019-02-21"/><FilterOption count="7" label="2019-03-21"/><FilterOption count="7" label="2019-04-23"/><FilterOption count="7" label="2019-05-16"/><FilterOption count="7" label="2019-05-30"/><FilterOption count="7" label="2019-06-08"/><FilterOption count="7" label="2019-06-15"/><FilterOption count="7" label="2019-06-29"/><FilterOption count="6" label="2013-09-13"/><FilterOption count="6" label="2018-05-19"/><FilterOption count="6" label="2018-05-29"/><FilterOption count="6" label="2018-11-22"/><FilterOption count="6" label="2018-11-28"/><FilterOption count="6" label="2019-01-09"/><FilterOption count="6" label="2019-02-19"/><FilterOption count="6" label="2019-02-22"/><FilterOption count="5" label="2018-01-23"/><FilterOption count="5" label="2018-06-08"/><FilterOption count="5" label="2018-11-13"/><FilterOption count="5" label="2018-11-16"/><FilterOption count="5" label="2018-11-21"/><FilterOption count="5" label="2018-11-27"/><FilterOption count="5" label="2019-01-18"/><FilterOption count="5" label="2019-01-28"/><FilterOption count="5" label="2019-02-06"/><FilterOption count="5" label="2019-02-20"/><FilterOption count="5" label="2019-02-26"/><FilterOption count="5" label="2019-03-01"/><FilterOption count="5" label="2019-03-15"/><FilterOption count="5" label="2019-03-18"/><FilterOption count="5" label="2019-03-20"/><FilterOption count="5" label="2019-04-02"/><FilterOption count="5" label="2019-04-12"/><FilterOption count="5" label="2019-04-24"/><FilterOption count="5" label="2019-04-25"/><FilterOption count="5" label="2019-05-03"/><FilterOption count="5" label="2019-05-09"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="37" label="201912"/><FilterOption count="25" label="202012"/><FilterOption count="22" label="202112"/><FilterOption count="21" label="202007"/><FilterOption count="20" label="201909"/><FilterOption count="19" label="201612"/><FilterOption count="19" label="202006"/><FilterOption count="18" label="201112"/><FilterOption count="18" label="201810"/><FilterOption count="18" label="201901"/><FilterOption count="18" label="202003"/><FilterOption count="17" label="201512"/><FilterOption count="17" label="201712"/><FilterOption count="17" label="202001"/><FilterOption count="16" label="201710"/><FilterOption count="16" label="201812"/><FilterOption count="16" label="202106"/><FilterOption count="15" label="201304"/><FilterOption count="15" label="201409"/><FilterOption count="15" label="201708"/><FilterOption count="15" label="201903"/><FilterOption count="15" label="201910"/><FilterOption count="15" label="201911"/><FilterOption count="15" label="202005"/><FilterOption count="15" label="202103"/><FilterOption count="14" label="201106"/><FilterOption count="14" label="201310"/><FilterOption count="14" label="201312"/><FilterOption count="14" label="201503"/><FilterOption count="14" label="201801"/><FilterOption count="14" label="201906"/><FilterOption count="13" label="201307"/><FilterOption count="13" label="201412"/><FilterOption count="13" label="201706"/><FilterOption count="13" label="201707"/><FilterOption count="13" label="201805"/><FilterOption count="13" label="201811"/><FilterOption count="13" label="201905"/><FilterOption count="13" label="201907"/><FilterOption count="13" label="202004"/><FilterOption count="12" label="201212"/><FilterOption count="12" label="201405"/><FilterOption count="12" label="201507"/><FilterOption count="12" label="201604"/><FilterOption count="12" label="201704"/><FilterOption count="12" label="201803"/><FilterOption count="12" label="201806"/><FilterOption count="12" label="201904"/><FilterOption count="12" label="202107"/><FilterOption count="12" label="202109"/><FilterOption count="11" label="201107"/><FilterOption count="11" label="201205"/><FilterOption count="11" label="201306"/><FilterOption count="11" label="201401"/><FilterOption count="11" label="201406"/><FilterOption count="11" label="201407"/><FilterOption count="11" label="201506"/><FilterOption count="11" label="201508"/><FilterOption count="11" label="201511"/><FilterOption count="11" label="201607"/><FilterOption count="11" label="201705"/><FilterOption count="11" label="202009"/><FilterOption count="11" label="202010"/><FilterOption count="11" label="202101"/><FilterOption count="11" label="202105"/><FilterOption count="11" label="202209"/><FilterOption count="10" label="201105"/><FilterOption count="10" label="201302"/><FilterOption count="10" label="201305"/><FilterOption count="10" label="201601"/><FilterOption count="10" label="201709"/><FilterOption count="10" label="201807"/><FilterOption count="10" label="201908"/><FilterOption count="10" label="202011"/><FilterOption count="10" label="202206"/><FilterOption count="9" label="201012"/><FilterOption count="9" label="201204"/><FilterOption count="9" label="201206"/><FilterOption count="9" label="201410"/><FilterOption count="9" label="201411"/><FilterOption count="9" label="201504"/><FilterOption count="9" label="201505"/><FilterOption count="9" label="201603"/><FilterOption count="9" label="201808"/><FilterOption count="9" label="201902"/><FilterOption count="9" label="202202"/><FilterOption count="9" label="202204"/><FilterOption count="9" label="202205"/><FilterOption count="8" label="200702"/><FilterOption count="8" label="201005"/><FilterOption count="8" label="201006"/><FilterOption count="8" label="201201"/><FilterOption count="8" label="201203"/><FilterOption count="8" label="201207"/><FilterOption count="8" label="201209"/><FilterOption count="8" label="201210"/><FilterOption count="8" label="201602"/><FilterOption count="8" label="201711"/><FilterOption count="8" label="201804"/><FilterOption count="8" label="201809"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="23" label="201706"/><FilterOption count="21" label="201701"/><FilterOption count="20" label="201509"/><FilterOption count="20" label="201707"/><FilterOption count="19" label="201506"/><FilterOption count="19" label="201606"/><FilterOption count="18" label="201001"/><FilterOption count="18" label="201212"/><FilterOption count="18" label="201711"/><FilterOption count="17" label="201210"/><FilterOption count="17" label="201402"/><FilterOption count="17" label="201512"/><FilterOption count="17" label="201710"/><FilterOption count="17" label="201810"/><FilterOption count="17" label="201811"/><FilterOption count="17" label="201812"/><FilterOption count="16" label="200909"/><FilterOption count="16" label="201411"/><FilterOption count="16" label="201503"/><FilterOption count="16" label="201704"/><FilterOption count="15" label="200812"/><FilterOption count="15" label="201110"/><FilterOption count="15" label="201111"/><FilterOption count="15" label="201204"/><FilterOption count="15" label="201310"/><FilterOption count="15" label="201604"/><FilterOption count="15" label="201805"/><FilterOption count="15" label="201806"/><FilterOption count="14" label="201006"/><FilterOption count="14" label="201102"/><FilterOption count="14" label="201201"/><FilterOption count="14" label="201206"/><FilterOption count="14" label="201407"/><FilterOption count="14" label="201410"/><FilterOption count="14" label="201412"/><FilterOption count="14" label="201504"/><FilterOption count="14" label="201611"/><FilterOption count="14" label="201803"/><FilterOption count="13" label="200711"/><FilterOption count="13" label="200712"/><FilterOption count="13" label="200806"/><FilterOption count="13" label="200808"/><FilterOption count="13" label="200912"/><FilterOption count="13" label="201011"/><FilterOption count="13" label="201109"/><FilterOption count="13" label="201207"/><FilterOption count="13" label="201301"/><FilterOption count="13" label="201309"/><FilterOption count="13" label="201312"/><FilterOption count="13" label="201403"/><FilterOption count="13" label="201405"/><FilterOption count="13" label="201610"/><FilterOption count="13" label="201703"/><FilterOption count="13" label="201705"/><FilterOption count="12" label="200610"/><FilterOption count="12" label="200902"/><FilterOption count="12" label="200904"/><FilterOption count="12" label="201007"/><FilterOption count="12" label="201009"/><FilterOption count="12" label="201012"/><FilterOption count="12" label="201101"/><FilterOption count="12" label="201105"/><FilterOption count="12" label="201401"/><FilterOption count="12" label="201404"/><FilterOption count="12" label="201406"/><FilterOption count="12" label="201602"/><FilterOption count="12" label="201603"/><FilterOption count="12" label="201609"/><FilterOption count="12" label="201807"/><FilterOption count="11" label="200603"/><FilterOption count="11" label="200903"/><FilterOption count="11" label="200907"/><FilterOption count="11" label="200911"/><FilterOption count="11" label="201008"/><FilterOption count="11" label="201103"/><FilterOption count="11" label="201107"/><FilterOption count="11" label="201205"/><FilterOption count="11" label="201305"/><FilterOption count="11" label="201501"/><FilterOption count="11" label="201605"/><FilterOption count="11" label="201702"/><FilterOption count="11" label="201801"/><FilterOption count="10" label="200801"/><FilterOption count="10" label="201003"/><FilterOption count="10" label="201004"/><FilterOption count="10" label="201010"/><FilterOption count="10" label="201202"/><FilterOption count="10" label="201203"/><FilterOption count="10" label="201306"/><FilterOption count="10" label="201307"/><FilterOption count="10" label="201311"/><FilterOption count="10" label="201507"/><FilterOption count="10" label="201511"/><FilterOption count="10" label="201607"/><FilterOption count="10" label="201709"/><FilterOption count="10" label="201802"/><FilterOption count="10" label="201804"/><FilterOption count="10" label="201808"/><FilterOption count="10" label="201809"/><FilterOption count="10" label="201901"/></Filter><Filter label="Trial Phase" name="trialPhase" total="14"><FilterOption id="C3" count="785" label="Phase 3 Clinical"/><FilterOption id="C2" count="456" label="Phase 2 Clinical"/><FilterOption id="C4" count="237" label="Phase 4 Clinical"/><FilterOption id="PNA" count="122" label="Phase Not Applicable"/><FilterOption id="C12" count="82" label="Phase 1/Phase 2 Clinical"/><FilterOption id="C3B" count="74" label="Phase 3b Clinical"/><FilterOption id="C2B" count="63" label="Phase 2b Clinical"/><FilterOption id="C1" count="53" label="Phase 1 Clinical"/><FilterOption id="C23" count="42" label="Phase 2/Phase 3 Clinical"/><FilterOption id="NS" count="36" label="Phase not specified"/><FilterOption id="C2A" count="29" label="Phase 2a Clinical"/><FilterOption id="C1B" count="26" label="Phase 1b Clinical"/><FilterOption id="C0" count="6" label="Phase 0 Clinical"/><FilterOption id="C3A" count="5" label="Phase 3a Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="5418" count="85" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"/><FilterOption id="4879" count="80" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4880" count="80" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3976" count="77" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3977" count="77" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5317" count="76" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"/><FilterOption id="4840" count="71" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3900" count="66" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3957" count="61" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"/><FilterOption id="3936" count="60" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"/><FilterOption id="5086" count="58" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5087" count="57" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4169" count="57" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4170" count="57" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3940" count="55" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3537" count="54" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="54" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4139" count="54" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="5088" count="52" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4814" count="49" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="4162" count="46" label="Melanoma - Subjects with Diagnosis of Melanoma - Subjects with histological diagnosis of melanoma"/><FilterOption id="4691" count="46" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4692" count="46" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3539" count="45" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="7091" count="45" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="5322" count="44" label="HIV infection - Subjects with Protocol Specified CD4+ T Cell Counts"/><FilterOption id="22381" count="44" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"/><FilterOption id="4981" count="43" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3914" count="43" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4126" count="42" label="Melanoma - Subjects with Advanced Melanoma"/><FilterOption id="4208" count="42" label="Melanoma - Subjects with Feasibility for Specific Treatment Modalities - Subjects with surgically non-resectable melanoma"/><FilterOption id="584" count="42" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"/><FilterOption id="4024" count="41" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="22417" count="40" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="4032" count="40" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3938" count="40" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"/><FilterOption id="4808" count="38" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="4922" count="38" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="5344" count="38" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="3548" count="38" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="4074" count="37" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4857" count="36" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4483" count="36" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="5074" count="36" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4767" count="36" label="Multiple myeloma - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="4817" count="35" label="Breast tumor - Postmenopausal Breast Cancer Women"/><FilterOption id="4813" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="4923" count="35" label="Breast tumor - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="3935" count="35" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"/><FilterOption id="4628" count="35" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum M-protein"/><FilterOption id="5073" count="34" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"/><FilterOption id="4106" count="34" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"/><FilterOption id="4693" count="34" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="5339" count="33" label="HIV infection - Treatment Naive Subjects"/><FilterOption id="3755" count="33" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="4894" count="32" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="5164" count="32" label="Leukemia - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="22405" count="32" label="Leukemia - Treatment Naive Subjects"/><FilterOption id="4756" count="32" label="Multiple myeloma - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4877" count="30" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"/><FilterOption id="4198" count="30" label="Melanoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4955" count="29" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="4527" count="29" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4528" count="29" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4672" count="29" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological status"/><FilterOption id="4675" count="29" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="13096" count="29" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4928" count="28" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4973" count="28" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="4203" count="28" label="Melanoma - Treatment Naive Subjects"/><FilterOption id="3933" count="27" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"/><FilterOption id="3642" count="27" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4147" count="27" label="Melanoma - Subjects with Evidence of Metastasis"/><FilterOption id="4630" count="27" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum/urine light chain"/><FilterOption id="4676" count="27" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="32953" count="27" label="Other gastrointestinal disease - Protocol Specified Other Inclusion Criteria"/><FilterOption id="3695" count="27" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="4864" count="26" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"/><FilterOption id="1751" count="26" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"/><FilterOption id="4041" count="26" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3971" count="26" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"/><FilterOption id="3614" count="26" label="Lymphoma - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="3738" count="26" label="Prostate tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod status 0-2"/><FilterOption id="13110" count="26" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="13111" count="26" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7465" count="25" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4509" count="25" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"/><FilterOption id="3622" count="25" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="7441" count="24" label="Bladder cancer - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7464" count="24" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4895" count="24" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer hormonal therapy"/><FilterOption id="4809" count="24" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="32043" count="24" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="3448" count="24" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="4629" count="24" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable urine M-protein"/><FilterOption id="3628" count="23" label="Lymphoma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3746" count="23" label="Prostate tumor - Subjects on Prior/Concurrent Therapy for Prostate Cancer - Subjects on prior/concurrent hormone therapy"/><FilterOption id="4140" count="22" label="Melanoma - Subjects with Measurable Disease"/><FilterOption id="13129" count="22" label="Solid tumor - Subjects with Treatment Refractory Disease"/><FilterOption id="4893" count="21" label="Breast tumor - Subjects with History of Anti Cancer Therapy"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="15" label="docetaxel"/><FilterOption id="13928" count="13" label="enoxaparin sodium"/><FilterOption id="7413" count="9" label="darbepoetin alfa"/><FilterOption id="3803" count="9" label="paclitaxel"/><FilterOption id="3313" count="8" label="fulvestrant"/><FilterOption id="37370" count="7" label="azacitidine"/><FilterOption id="3199" count="7" label="gemcitabine"/><FilterOption id="11460" count="7" label="imatinib"/><FilterOption id="4529" count="7" label="temozolomide"/><FilterOption id="12205" count="6" label="capecitabine"/><FilterOption id="29831" count="6" label="sorafenib"/><FilterOption id="4510" count="6" label="tacrolimus"/><FilterOption id="2784" count="5" label="letrozole"/><FilterOption id="12973" count="5" label="sunitinib"/><FilterOption id="44401" count="5" label="vancomycin"/><FilterOption id="5267" count="4" label="leuprorelin acetate"/><FilterOption id="6050" count="4" label="metformin hydrochloride"/><FilterOption id="54804" count="4" label="nivolumab"/><FilterOption id="70667" count="4" label="pembrolizumab"/><FilterOption id="4577" count="4" label="topotecan"/><FilterOption id="44375" count="4" label="warfarin"/><FilterOption id="14163" count="3" label="adalimumab"/><FilterOption id="3321" count="3" label="anastrozole"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="7934" count="3" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="53981" count="3" label="enzalutamide"/><FilterOption id="36630" count="3" label="ipilimumab"/><FilterOption id="3669" count="3" label="mycophenolate mofetil"/><FilterOption id="42299" count="3" label="ofatumumab"/><FilterOption id="8713" count="3" label="sildenafil citrate"/><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"/><FilterOption id="54469" count="3" label="vemurafenib"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="44388" count="2" label="carbidopa + levodopa"/><FilterOption id="12544" count="2" label="caspofungin"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="2992" count="2" label="donepezil hydrochloride"/><FilterOption id="10172" count="2" label="efavirenz"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="67892" count="2" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"/><FilterOption id="11961" count="2" label="erlotinib"/><FilterOption id="3081" count="2" label="exemestane"/><FilterOption id="3350" count="2" label="Fluarix"/><FilterOption id="55237" count="2" label="ibrutinib"/><FilterOption id="10252" count="2" label="insulin glargine"/><FilterOption id="3360" count="2" label="interferon beta-1a, Biogen"/><FilterOption id="2871" count="2" label="irinotecan"/><FilterOption id="33591" count="2" label="lapatinib"/><FilterOption id="14681" count="2" label="lopinavir + ritonavir"/><FilterOption id="12978" count="2" label="moxifloxacin"/><FilterOption id="2534" count="2" label="omalizumab"/><FilterOption id="43738" count="2" label="pazopanib"/><FilterOption id="22395" count="2" label="ranibizumab"/><FilterOption id="44313" count="2" label="simvastatin"/><FilterOption id="36213" count="2" label="teriflunomide"/><FilterOption id="42858" count="2" label="ustekinumab"/><FilterOption id="6408" count="2" label="vinorelbine"/><FilterOption id="2765" count="2" label="zoledronic acid"/><FilterOption id="44374" count="1" label="amiodarone"/><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"/><FilterOption id="52967" count="1" label="apixaban"/><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"/><FilterOption id="15254" count="1" label="atazanavir"/><FilterOption id="72699" count="1" label="atezolizumab"/><FilterOption id="16905" count="1" label="atomoxetine"/><FilterOption id="2807" count="1" label="atorvastatin"/><FilterOption id="29671" count="1" label="AZA-DR"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="100071" count="1" label="BMS-986177"/><FilterOption id="30379" count="1" label="bosutinib"/><FilterOption id="50935" count="1" label="cabozantinib S-malate"/><FilterOption id="4522" count="1" label="candesartan"/><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"/><FilterOption id="44383" count="1" label="carboplatin"/><FilterOption id="95204" count="1" label="cemiplimab"/><FilterOption id="10388" count="1" label="cetuximab"/><FilterOption id="5999" count="1" label="ciclosporin, Novartis"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="53133" count="1" label="dabrafenib"/><FilterOption id="2911" count="1" label="daptomycin"/><FilterOption id="72148" count="1" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="72153" count="1" label="darunavir + tenofovir alafenamide + emtricitabine + cobicistat (single tablet regimen, HIV-1),Janssen R&amp;D"/><FilterOption id="69973" count="1" label="dolutegravir + lamivudine + abacavir (HIV), ViiV"/><FilterOption id="15593" count="1" label="eculizumab"/><FilterOption id="6047" count="1" label="eflornithine"/><FilterOption id="4728" count="1" label="emtricitabine"/><FilterOption id="44289" count="1" label="enalapril"/><FilterOption id="3268" count="1" label="Engerix B"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="14603" count="1" label="eplerenone"/><FilterOption id="6797" count="1" label="epoetin alfa (Epogen), Amgen"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="13340" count="1" label="everolimus"/><FilterOption id="11367" count="1" label="ezetimibe"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="3159" count="1" label="fluticasone propionate"/><FilterOption id="11603" count="1" label="gefitinib"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="1016" count="25" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="1832" count="24" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="372" count="24" label="Thymidylate synthase inhibitor"/><FilterOption id="3808" count="22" label="Kit tyrosine kinase inhibitor"/><FilterOption id="5085" count="20" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="204" count="19" label="HIV protease inhibitor"/><FilterOption id="142" count="18" label="Topoisomerase II inhibitor"/><FilterOption id="768" count="17" label="HIV-1 protease inhibitor"/><FilterOption id="3846" count="17" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="17" label="VEGF-2 receptor antagonist"/><FilterOption id="1741" count="16" label="Low molecular weight heparin"/><FilterOption id="138" count="15" label="DNA polymerase inhibitor"/><FilterOption id="740" count="15" label="Epidermal growth factor receptor antagonist"/><FilterOption id="3756" count="15" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="3850" count="15" label="VEGF-3 receptor antagonist"/><FilterOption id="4010" count="14" label="Calcineurin inhibitor"/><FilterOption id="7424" count="14" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="948" count="14" label="PDGF receptor antagonist"/><FilterOption id="48492" count="14" label="PDGF receptor beta antagonist"/><FilterOption id="3806" count="13" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="4917" count="13" label="Proteasome inhibitor"/><FilterOption id="3816" count="13" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="76" count="12" label="Aromatase inhibitor"/><FilterOption id="67136" count="11" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="4548" count="11" label="Raf B protein kinase inhibitor"/><FilterOption id="6512" count="10" label="DNA methyltransferase inhibitor"/><FilterOption id="12162" count="10" label="Erythropoietin ligand"/><FilterOption id="7588" count="10" label="HIV-1 integrase inhibitor"/><FilterOption id="629" count="10" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="76469" count="9" label="26S proteasome complex inhibitor"/><FilterOption id="286" count="9" label="Estrogen receptor antagonist"/><FilterOption id="11778" count="9" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="374" count="9" label="Transferase inhibitor"/><FilterOption id="1722" count="9" label="VEGF receptor antagonist"/><FilterOption id="3524" count="8" label="Abl tyrosine kinase inhibitor"/><FilterOption id="8805" count="8" label="AMP activated protein kinase stimulator"/><FilterOption id="135" count="8" label="DHFR inhibitor"/><FilterOption id="111" count="8" label="Factor IIa antagonist"/><FilterOption id="113" count="8" label="Factor IX antagonist"/><FilterOption id="114" count="8" label="Factor VII antagonist"/><FilterOption id="119" count="8" label="Factor X antagonist"/><FilterOption id="181" count="8" label="GAR transformylase inhibitor"/><FilterOption id="71851" count="8" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="12395" count="8" label="HIV GAG protein inhibitor"/><FilterOption id="23014" count="8" label="Insulin ligand"/><FilterOption id="400" count="8" label="Insulin receptor agonist"/><FilterOption id="1833" count="8" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="48489" count="8" label="PDGF receptor alpha antagonist"/><FilterOption id="141" count="8" label="Topoisomerase I inhibitor"/><FilterOption id="814" count="8" label="Tubulin modulator"/><FilterOption id="12521" count="8" label="VEGF ligand inhibitor"/><FilterOption id="10583" count="8" label="Vitamin K epoxide reductase inhibitor"/><FilterOption id="13571" count="7" label="Bcr protein inhibitor"/><FilterOption id="7472" count="7" label="Cytochrome P450 17 inhibitor"/><FilterOption id="7025" count="7" label="Signal transduction inhibitor"/><FilterOption id="3154" count="6" label="CSF-1 antagonist"/><FilterOption id="7418" count="6" label="Cytochrome P450 3 inhibitor"/><FilterOption id="431" count="6" label="DNA gyrase inhibitor"/><FilterOption id="214" count="6" label="Interferon alpha 2 ligand"/><FilterOption id="4913" count="6" label="P2Y12 purinoceptor antagonist"/><FilterOption id="57003" count="6" label="Peptidoglycan recognition protein inhibitor"/><FilterOption id="4550" count="6" label="Raf 1 protein kinase inhibitor"/><FilterOption id="4542" count="6" label="Raf protein kinase inhibitor"/><FilterOption id="5482" count="5" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="82444" count="5" label="DNA helicase inhibitor"/><FilterOption id="10240" count="5" label="mTOR inhibitor"/><FilterOption id="2506" count="5" label="PARP modulator"/><FilterOption id="381" count="5" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="5" label="TNF binding agent"/><FilterOption id="60" count="4" label="Androgen receptor antagonist"/><FilterOption id="7423" count="4" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="6515" count="4" label="Cytosine DNA methyltransferase inhibitor"/><FilterOption id="18889" count="4" label="DNA binding protein inhibitor"/><FilterOption id="1092" count="4" label="GNRH receptor agonist"/><FilterOption id="1671" count="4" label="HIV integrase inhibitor"/><FilterOption id="205" count="4" label="HMG CoA reductase inhibitor"/><FilterOption id="777" count="4" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="76090" count="4" label="mTOR complex 1 inhibitor"/><FilterOption id="778" count="4" label="PDE 5 inhibitor"/><FilterOption id="35354" count="4" label="Prostate specific antigen modulator"/><FilterOption id="346" count="4" label="Ribonucleotide reductase inhibitor"/><FilterOption id="1513" count="4" label="Topoisomerase II modulator"/><FilterOption id="9320" count="4" label="Topoisomerase IV inhibitor"/><FilterOption id="78089" count="4" label="Translocation associated protein inhibitor"/><FilterOption id="61991" count="3" label="1,3 beta glucan synthase inhibitor"/><FilterOption id="18" count="3" label="ACE inhibitor"/><FilterOption id="5136" count="3" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="64" count="3" label="Angiotensin II receptor antagonist"/><FilterOption id="40" count="3" label="Beta 2 adrenoceptor agonist"/><FilterOption id="1716" count="3" label="Dihydroorotate dehydrogenase inhibitor"/><FilterOption id="51708" count="3" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="3" label="DNA primase inhibitor"/><FilterOption id="5554" count="3" label="Dopa decarboxylase inhibitor"/><FilterOption id="144" count="3" label="Dopamine receptor agonist"/><FilterOption id="3754" count="3" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="675" count="3" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="481" count="3" label="Interferon beta ligand"/><FilterOption id="3796" count="3" label="MET tyrosine kinase receptor family inhibitor"/><FilterOption id="262" count="3" label="Muscarinic M3 receptor antagonist"/><FilterOption id="38283" count="3" label="Poly ADP ribose polymerase 1 inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="327" label="Diarrhea"/><FilterOption id="226" count="301" label="Nausea"/><FilterOption id="829" count="249" label="Fatigue"/><FilterOption id="1991" count="204" label="Neutropenia"/><FilterOption id="17" count="191" label="Anemia"/><FilterOption id="148" count="185" label="Headache"/><FilterOption id="110" count="171" label="Emesis"/><FilterOption id="324" count="156" label="Thrombocytopenia"/><FilterOption id="3020" count="128" label="Skin rash"/><FilterOption id="1833" count="119" label="Fever"/><FilterOption id="404" count="110" label="Constipation"/><FilterOption id="3038" count="109" label="Appetite loss"/><FilterOption id="3062" count="102" label="Death"/><FilterOption id="178" count="102" label="Hypertension"/><FilterOption id="360" count="97" label="Pneumonia"/><FilterOption id="2274" count="95" label="Rhinopharyngitis"/><FilterOption id="746" count="87" label="Infectious disease"/><FilterOption id="516" count="77" label="Upper respiratory tract infection"/><FilterOption id="2439" count="74" label="Arthralgia"/><FilterOption id="82" count="70" label="Cough"/><FilterOption id="402" count="70" label="Edema"/><FilterOption id="3472" count="67" label="Abdominal pain"/><FilterOption id="3221" count="65" label="Back pain"/><FilterOption id="3454" count="64" label="Dizziness"/><FilterOption id="680" count="62" label="Leukopenia"/><FilterOption id="2400" count="61" label="Dyspnea"/><FilterOption id="3795" count="58" label="Febrile neutropenia"/><FilterOption id="279" count="53" label="Pruritus"/><FilterOption id="1009" count="52" label="Urinary tract infection"/><FilterOption id="20" count="49" label="Pain"/><FilterOption id="552" count="48" label="Bleeding"/><FilterOption id="13" count="46" label="Alopecia"/><FilterOption id="1039" count="45" label="Myalgia"/><FilterOption id="750" count="42" label="Insomnia"/><FilterOption id="1821" count="38" label="Hyperglycemia"/><FilterOption id="259" count="38" label="Peripheral neuropathy"/><FilterOption id="50" count="34" label="Bronchitis"/><FilterOption id="129" count="32" label="Gastrointestinal disease"/><FilterOption id="114" count="28" label="Sepsis"/><FilterOption id="1016" count="28" label="Stomatitis"/><FilterOption id="93" count="26" label="Depression"/><FilterOption id="181" count="26" label="Hypokalemia"/><FilterOption id="1078" count="26" label="Lung embolism"/><FilterOption id="1992" count="26" label="Lymphocytopenia"/><FilterOption id="224" count="26" label="Myocardial infarction"/><FilterOption id="191" count="25" label="Influenza virus infection"/><FilterOption id="408" count="23" label="Hypotension"/><FilterOption id="1072" count="22" label="Colitis"/><FilterOption id="2955" count="22" label="Weight loss"/><FilterOption id="432" count="21" label="Dyspepsia"/><FilterOption id="445" count="21" label="Hypoglycemia"/><FilterOption id="574" count="20" label="Deep vein thrombosis"/><FilterOption id="69" count="20" label="Renal failure"/><FilterOption id="3073" count="19" label="Drowsiness"/><FilterOption id="2576" count="19" label="Dysgeusia"/><FilterOption id="182" count="19" label="Hypothyroidism"/><FilterOption id="3050" count="18" label="Chill"/><FilterOption id="2434" count="18" label="Vertigo"/><FilterOption id="1280" count="17" label="Hypophosphatemia"/><FilterOption id="505" count="16" label="Hypersensitivity"/><FilterOption id="678" count="16" label="Neuropathy"/><FilterOption id="277" count="16" label="Proteinuria"/><FilterOption id="325" count="16" label="Thromboembolism"/><FilterOption id="1559" count="15" label="Congestive heart failure"/><FilterOption id="2024" count="15" label="Erythema"/><FilterOption id="358" count="15" label="Muscle spasm"/><FilterOption id="2440" count="15" label="Musculoskeletal pain"/><FilterOption id="65" count="15" label="Stroke"/><FilterOption id="25" count="14" label="Anxiety disorder"/><FilterOption id="55" count="14" label="Cardiac failure"/><FilterOption id="172" count="14" label="Hyperbilirubinemia"/><FilterOption id="250" count="14" label="Pancreatitis"/><FilterOption id="286" count="14" label="Renal disease"/><FilterOption id="1063" count="14" label="Xerostomia"/><FilterOption id="1542" count="13" label="Atrial fibrillation"/><FilterOption id="57" count="13" label="Cardiovascular disease"/><FilterOption id="154" count="13" label="Hepatitis"/><FilterOption id="201" count="13" label="Liver disease"/><FilterOption id="307" count="13" label="Squamous cell carcinoma"/><FilterOption id="1876" count="13" label="Syncope"/><FilterOption id="95" count="12" label="Dermatological disease"/><FilterOption id="1835" count="12" label="Epistaxis"/><FilterOption id="2195" count="12" label="Gastroenteritis"/><FilterOption id="174" count="12" label="Hypercholesterolemia"/><FilterOption id="179" count="12" label="Hyperthyroidism"/><FilterOption id="1256" count="12" label="Hyponatremia"/><FilterOption id="2954" count="12" label="Weight gain"/><FilterOption id="392" count="11" label="Varicella zoster virus infection"/><FilterOption id="1091" count="10" label="Bone injury"/><FilterOption id="2525" count="10" label="Cellulitis"/><FilterOption id="444" count="10" label="Hypocalcemia"/><FilterOption id="1263" count="10" label="Mucositis"/><FilterOption id="31" count="9" label="Asthma"/><FilterOption id="2184" count="9" label="Gastrointestinal bleeding"/><FilterOption id="2112" count="9" label="Hyperkeratosis"/><FilterOption id="2733" count="9" label="Hypomagnesemia"/><FilterOption id="1061" count="9" label="Sinusitis"/><FilterOption id="2948" count="9" label="Tumor lysis syndrome"/><FilterOption id="412" count="8" label="Bradycardia"/><FilterOption id="651" count="8" label="Cancer"/></Filter></Filters><SearchResults><Trial Id="234533"><Indications><Indication>Advanced solid tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>UK</Country></Countries><DateChangeLast>2015-11-19T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>2004-01-31T00:00:00Z</DateStart><Identifiers><Identifier>BO17003</Identifier><Identifier>NCT02494596</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capecitabine plus pertuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4 (Perjeta) and capecitabine (Xeloda) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy was available.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Solid tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors</TitleDisplay><PatientSegmentTerms><PatientSegment>Solid tumor - Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2005-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="329598"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesCollaborator><Company>Oblikue Consulting</Company></CompaniesCollaborator><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-03-01T00:00:00Z</DateChangeLast><DateEnd>2018-07-31T00:00:00Z</DateEnd><DateStart>2017-12-05T00:00:00Z</DateStart><Identifiers><Identifier>206555</Identifier><Identifier>NCT03436511</Identifier></Identifiers><PatientCountEnrollment>354</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biological treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Clinical Symptoms - Assessment of anxiety</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum fibrinogen assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum - Sputum eosinophils</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - COPD Assessment Test(CAT)Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - EuroQol (EQ-5D)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with specific cigarette smoking activity</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Fibrinogen </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Red cell distribution width </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>EU GSK Clinical Trials Call Center</Name><Name>GSK Clinical Trials</Name><Name>US GSK Clinical Trials Call Center</Name></ContactNames></Trial><Trial Id="57933"><Indications><Indication>Familial adenomatous polyposis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Denmark</Country><Country>Canada</Country><Country>US</Country><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2008-11-30T00:00:00Z</DateEnd><DateStart>2004-11-30T00:00:00Z</DateStart><Identifiers><Identifier>A3191167</Identifier><Identifier>NCT00151476</Identifier><Identifier>NQ4-00-02-012</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Back pain</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>celecoxib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this registry-based observational study was to assess clinical outcomes in Familial Adenomatous Polyposis (FAP) patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib . Both retrospective and prospective data were utilized. No sampling methods apply.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Change in burden of illness and treatment over time</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adenomatous polyposis coli protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="37979"><Indications><Indication>Hepatocellular carcinoma</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatocyte growth factor receptor antagonist</Action><Action>MET gene modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>ArQule Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Spain</Country><Country>US</Country></Countries><DateChangeLast>2018-05-28T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2009-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ARQ 197-114</Identifier><Identifier>NCT00802555</Identifier></Identifiers><IndicationsAdverse><Indication>Alopecia</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Bradycardia</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication><Indication>Pneumonia</Indication><Indication>Sepsis</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tivantinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This multicenter, single-arm, phase Ib study was designed to evaluate safety and tolerability of ARQ-197 in cirrhotic patients with hepatocellular carcinoma (HCC).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular endothelial growth factor (VEGF)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Oncogenes/Oncoproteins - Assessment of hepatocyte growth factor (HGF)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety Study of ARQ-197 in Cirrhotic Patients With Carcinoma (HCC)</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatobiliary system tumor - Subjects with Elevated Alpha-fetoprotein (AFP) levels</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with specific disease - Subjects with hepatocellular carcinoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alpha-fetoprotein </BiomarkerName><BiomarkerName> Hepatocyte growth factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>5</NumberOfSites></Trial><Trial Id="13518"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein recombinant</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Malaysia</Country><Country>Czech Republic</Country><Country>Spain</Country></Countries><DateChangeLast>2017-07-05T00:00:00Z</DateChangeLast><DateEnd>2004-01-31T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>208129/047</Identifier><Identifier>EXT:HBV-MPL-032</Identifier><Identifier>NCT00383591</Identifier></Identifiers><IndicationsAdverse><Indication>Abscess</Indication><Indication>Anemia</Indication><Indication>Arthralgia</Indication><Indication>Cataract</Indication><Indication>Dizziness</Indication><Indication>Dyspnea</Indication><Indication>Gangrene</Indication><Indication>Heart arrhythmia</Indication><Indication>Renal colic</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Engerix B alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Fendrix alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was a phase III trial to compare the persistance of GSK Biologicals ' new adjuvated hepatitis B vaccine, Fendrix to a double dose of Engerix B in pre-hemodialysis and hemodialysis patients aged 15 years or above. The study was to evaluate the persistance of the anti-HBs antibodies at months 24, 30, and 36, in subjects who had completed primary vaccination evaluation. The anamnestic response to the booster dose was to be evaluated in subjects with anti HBs antibody titer &amp;lt; 10 mIU/ml at</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>End stage renal disease - Overall Disease Activity Assessment - Assessment of disease remission/treatment response</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix B in Pre-Hemodialysis/Hemodialysis Patients Aged &gt;/= 15 Years</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects at risk of developing disease - Subjects on dialysis</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects with Prior Other Vaccination</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Hepatitis B Vaccination</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects at risk of developing disease - Subjects with dialysis as a risk factor</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with Prior Other Vaccination</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with Prior Other Vaccination - Subjects with Prior Hepatitis B Vaccination</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>22 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="286079"><Indications><Indication>Epilepsy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cannabinoid CB1 receptor modulator</Action><Action>Cannabinoid CB2 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticonvulsant agent</Action><Action>Antiparkinsonian</Action><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>GW Research Limited</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2017-06-07T00:00:00Z</DateEnd><DateStart>2016-03-11T00:00:00Z</DateStart><Identifiers><Identifier>2014-002942-33</Identifier><Identifier>GWEP1428 OPEN-LABEL EXTENSION</Identifier><Identifier>NCT02564952</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cannabidiol alone</Intervention><Intervention>clobazam alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the possible drug-drug interactions between clobazam and cannabidiol .</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Epilepsy - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Epilepsy - Assessment of adverse events</EndpointIndex><EndpointIndex>Epilepsy - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Epilepsy - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>An Open-label, Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol</TitleDisplay><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-06-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>6</NumberOfSites></Trial><Trial Id="46210"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule stabilizer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-06-24T00:00:00Z</DateChangeLast><DateEnd>2008-04-30T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00337649</Identifier><Identifier>NO17328</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>KOS-862 plus trastuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This single-arm study was designed to determine the efficacy and safety of an KOS-862 and Herceptin combination regimen in patients with HER-2 positive locally advanced or metastatic breast cancer. The target sample size would be &amp;lt; 100 individuals.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="68570"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-13T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-013780-19</Identifier><Identifier>CRAD001AES07</Identifier><Identifier>EVITA</Identifier><Identifier>NCT01169701</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including enteric-coated mycophenolate sodium, Novartis , mycophenolate mofetil , tacrolimus (oral sustained-release), Astellas</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including enteric-coated mycophenolate sodium, Novartis , everolimus , mycophenolate mofetil , tacrolimus (oral sustained-release), Astellas</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>71</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiac Function - Incidence of cardiovascular events/diseases</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance - Creatinine clearance using Cockcroft-Gault formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Imaging/Radiological Assessments - Assessment by imaging/radiology</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>EVITA: 24 Months Follow-up, Two-Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus A Regimen of CNI + MPA in Maintenance Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> C-terminal telopeptide of collagen type I </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Left ventricle </BiomarkerName><BiomarkerName> Myeloperoxidase </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Procollagen Type I N-terminal peptide </BiomarkerName><BiomarkerName> Pulse wave velocity </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="375257"><Indications><Indication>Myasthenia gravis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IgG receptor FcRn large subunit p51 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology></Technologies><CompaniesSponsor><Company>Momenta Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country><Country>Spain</Country></Countries><DateChangeLast>2019-04-02T00:00:00Z</DateChangeLast><DateEnd>2021-03-31T00:00:00Z</DateEnd><DateStart>2019-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2018-003618-41</Identifier><Identifier>MOM-M281-005</Identifier><Identifier>NCT03896295</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>M-281, Momenta Pharmaceuticals/AnaptysBio alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The purpose of this study is to evaluate the long-term safety and tolerability of M-281 in patients with generalized myasthenia gravis (gMG).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function - Assessment of Myasthenia Gravis Activities of Daily Living (MG-ADL) total score</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments - Myasthenia Gravis-Quality of Life 15 questionnaire (MG-QOL 15)</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments - Quantitative myasthenia gravis (QMG) score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability and Efficacy of M-281 Administered to Patients With Generalized Myasthenia Gravis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with myasthenia gravis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin G</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Momenta General Queries</Name></ContactNames></Trial><Trial Id="280538"><Indications><Indication>Metastatic non small cell lung cancer</Indication><Indication>Stage IV melanoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclin-dependent kinase-4 inhibitor</Action><Action>Cyclin-dependent kinase-6 inhibitor</Action><Action>Extracellular signal related kinase inhibitor</Action><Action>MEK-1 protein kinase inhibitor</Action><Action>MEK-2 protein kinase inhibitor</Action><Action>Raf 1 protein kinase inhibitor</Action><Action>Raf B protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>France</Country><Country>Italy</Country><Country>Spain</Country><Country>Australia</Country><Country>US</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2021-01-12T00:00:00Z</DateEnd><DateStart>2017-02-24T00:00:00Z</DateStart><Identifiers><Identifier>2016-004293-18</Identifier><Identifier>CLXH254X2102</Identifier><Identifier>NCT02974725</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including LTT-462 , LXH-254 , ribociclib , trametinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>195</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to characterize safety and tolerability and identify a recommended dose and regimen for the LXH-254 and LTT-462 combination and for the LXH-254 and trametinib or ribociclib combination.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response - Assessment of best overall response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase Ib Study of LXH-254-centric Combinations in NSCLC or Melanoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - BRAF_HUMAN_Mutation</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - KRAS_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-Raf proto-oncogene serine/threonine-protein kinase </BiomarkerName><BiomarkerName> Dual specificity protein phosphatase 6 </BiomarkerName><BiomarkerName> GTPase KRas</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-17T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Bakhan Barzangy</Name><Name>Novartis Pharmaceuticals</Name><Name>Rebecca Heist</Name></ContactNames></Trial></SearchResults></trialResultsOutput>